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 Chapter 1 Introduction 
1.1 The importance of the development of proper dendritic and axonal morphology  
 The development of proper neuronal morphology is critical for nervous system function. 
The brain is composed electrically excitable cells, neurons, which transmit signals through both 
electrical and chemical means. Neurons are typically composed of two distinct polarized 
compartments, the dendrites and the axon. Dendrites receive and process signals, while axons 
take that information and pass it on to other cells. To perform these two distinctive functions, 
axons and dendrites each have characteristic machinery and morphology. Diverse neuronal 
morphologies reflect the diverse functions that specific neuronal types must carry out, and 
defects in the development of neuronal morphology can lead to defective nervous system 
function. On the dendritic side of the neuron, defects in dendrite and dendritic spine morphology 
have been linked to many developmental disorders, where characteristic spine defects are 
hypothesized to impact information processing and synaptic transmission (Kaufmann and Moser, 
2000). On the axonal side of the neuron, defects in axon growth and pathfinding may lead to 
improper synaptic connections that interfere with circuit development and function. 
1.1.1 Mechanisms underlying the development of the presynaptic arbors 
 Several steps during development determine final axonal morphology. First, the axon 
must be properly specified and differentiated from the dendrites. Second, the axon enters a phase 
of rapid growth, during which it elongates toward its target. Third, upon reaching its target the 
axon forms local elongations, or presynaptic arbors, which interface with the target cell or cells. 
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Fourth, synapses form at sites throughout the presynaptic arbor, allowing for neural transmission. 
This dissertation focuses on the third step of axon development, the development of the 
presynaptic arbor. These processes are best studied in the neuromuscular junction (NMJ), where 
peripherally located motor neuron presynaptic arbors impinge on postsynaptic muscle fibers. 
 In mammals, NMJ development begins with the prepatterning of acetylcholine receptors 
(AChRs) to the central band of the developing muscle. Following interaction of the motor neuron 
axon with the muscle, postsynaptic AChR clusters form to perfectly appose the sites of motor 
axon impingement. These clusters form both by recruiting existing AChRs from the prepatterned 
band and by targeted accumulation of newly-generated AChRs. Trans-synaptic signals between 
the pre-synaptic motor axon and the post-synaptic myotubule coordinate these steps. A number 
of key molecular players in these events have been uncovered, including agrin, MuSK, Lrp4, and 
Dok-7.  
 Agrin is a heparin sulfate proteoglycan that is released from the motor neuron onto the 
muscle membrane. While not required for AChR prepatterning (Lin et al., 2001), agrin acts as a 
motor neuron-derived signal that organizes many aspects of NMJ development (Rupp et al., 
1991; Smith et al., 1987). Exposure of the postsynaptic muscle to agrin leads to phosphorylation 
of the AChR-β subunit, which triggers the redistribution of AChRs into clusters at the sites of 
motor neuron impingement (Wallace, 1986). Loss of agrin also leads to presynaptic defects in 
the NMJ. Most notably, motor axons in agrin-deficient mice leave the nerve tract, as in wildtype 
mice, but then fail to form presynaptic arbors terminating on myotubes, instead running parallel 
to the myotubules without branching (Gautam et al., 1996). Thus, agrin is important for the 
proper growth and patterning of both the pre- and post-synaptic sides of the NMJ.  
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 On the muscle side of the synapse, agrin’s receptor, muscle-specific kinase (MuSK) 
accumulates along with AChRs to the central band of the developing muscle. MuSK is a 
transmembrane receptor tyrosine kinase that is both necessary and sufficient to induce the entire 
post-synaptic apparatus (Kim et al., 2008; Sander et al., 2001), and MuSK mutants lack AChR 
clusters. Like agrin mutants, motor axons in mice lacking MuSK grow beyond the central region 
of the muscle and extend along the entire myotubule, but no pre-synaptic structures can be 
appreciated (DeChiara et al., 1996). Interestingly, however, MuSK does not bind directly to 
agrin. The interaction between agrin and MuSK is mediated by low-density lipoprotein receptor-
related protein 4 (Lrp4), an agrin-binding protein that forms a receptor complex with MuSK 
(Kim et al., 2008; Zhang et al., 2008). Loss of Lrp4 causes complete abrogation of NMJ 
development if deleted in both the motor neuron and the muscle (Weatherbee et al., 2006). 
 Activation of the MuSK-Lrp4 complex by agrin leads to the phosphorylation of a non-
catalytic cytoplasmic adaptor protein, Downstream of tyrosine kinases-7 (Dok-7), which serves 
as a promiscuous adaptor protein for tyrosine kinases. Dok-7 mutants lack NMJs, and have a 
similar phenotype to Argin-, MuSK- and Lrp4-deficient mice in that the motor axons fail to form 
presynaptic specializations and instead grow along the entire length of the myotubule (Okada et 
al., 2006). Phosphorylation of Dok-7 creates binding sites for v-crk sarcoma virus CT10 
oncogene homolog (Crk) and Crk-like (Crk-L). Newborn mice that lack Crk and Crk-L 
specifically in muscle die at birth due to respiratory failure, and closer inspection of their NMJs 
reveals a variety of defects. Although NMJs form in these mutants, motor axons are not confined 
within a narrow band on the myotubule and instead spread out over a wider region. In addition, 
synaptic size is reduced in mice that lacked Crk and Crk-L in muscle and motor axons frequently 
contacted AChR clusters but then continued to grow. This was in contrast to wild-type mice, 
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where motor axons terminated on AChR clusters (Hallock et al., 2010). Thus, Crk and Crk-L 
may play a role in regulating the size and patterning of NMJs in mammals. 
 Patterning and growth of NMJs vertebrates may also be regulated by Wnt signaling in 
vertebrates. Wnts are known to be involved in axon pathfinding and synaptogenesis, and the 
roles of Wnts in vertebrate NMJ development have been best studied in zebrafish. As in mice, 
deletion of the zebrafish ortholog of mammalian MuSK, unplugged, leads to a loss of AChR 
prepatterning and impairs guidance of motor axons to the central band of the myotubule. In 
addition to MuSK, Wnt11r is required to confine developing motor axons to the central region of 
the myotubule and for prepatterning of AChRs. Wnt11r binds to MuSK and is thought to signal 
through downstream dishevelled (Jing et al., 2009). Thus, in vertebrates, it seems that Wnts are 
important for controlling NMJ size and patterning.  
 In addition to mammalian studies, analysis of NMJ development in Drosophila has 
contributed much to our understanding of presynaptic arbor development. The advantages of 
using Drosophila include fast generation times, stereotyped morphology, and an extensive 
genetic toolkit. In Drosophila, NMJ presynaptic arbor development is regulated by trans-
synaptic signals, including Wingless (Wg), which belongs to the Wnt family, and Glass bottom 
boat (Gbb), part of the bone morphogenetic protein (BMP) and transforming growth factor-β 
(TGFβ) family. Both Wg and Gbb signal to the nucleus, presumably leading to changes in gene 
expression. Wg is secreted by motor neuron axon terminals, where is subsequently binds to the 
Wg receptor, DFrizzled2 (DFz2) on the post-synaptic membrane. Loss of both Wg and DFz2 
lead to defects in presynaptic arbor growth, and flies mutant for either protein exhibit smaller 
NMJ presynaptic arbors with fewer boutons (Mathew et al., 2005; Packard et al., 2002). These 
defects can be rescued by postsynaptic expression of DFz2, suggesting that a yet unidentified 
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retrograde signaling mechanism allows the muscle to stimulate presynaptic arbor growth in 
response to Wg secretion (Ataman et al., 2006). In contrast, release of Gbb from the postsynaptic 
muscle stimulates the BMP/TGFβ receptors Wit, Tkv and Sax on the presynaptic motor neuron 
which leads to phosphorylation of MAD. Phospho-MAD then translocates to the motor neuron 
nucleus, presumably leading to changes in gene expression that affect presynaptic arbor growth 
(Marques, 2005).  
 Although both Wg and Gbb signal to the nucleus, changes in presynaptic arbor growth 
are ultimately transduced by proteins that lead to local changes in the cytoskeleton and 
membrane. Previous studies have demonstrated roles for actin regulators like Nervous Wreck 
(Coyle et al., 2004) and WAVE/SCAR complex components (Schenck et al., 2004), microtubule 
regulators like Shaggy (Franco et al., 2004) and spastin (Trotta et al., 2004), cell adhesion 
molecules including Fasciclin II and Amyloid Precursor Protein(Ashley et al., 2005), and finally 
regulators of membrane trafficking (Dickman et al., 2006; Koh et al., 2004). Furthermore, 
although factors that promote growth are essential to presynaptic arbor development, it is also 
important to prevent excessive growth. Highwire (Hiw), an E3 ubiquitin ligase, is an 
evolutionarily conserved negative regulator of presynaptic arbor growth (Wu et al., 2005). Loss 
of Hiw function leads to huge increases in presynaptic arbor growth, resulting in excesses of both 
presynaptic arbor branches and boutons. Furthermore, Hiw requires Wallenda (Wnd), a mitogen-
activated protein kinase (MAPK) kinase kinase (MAPKKK) (Collins et al., 2006). The role of 
Hiw in regulating presynaptic arbor growth suggests that local control over protein degradation 
and synthesis may be essential to regulating presynaptic arbor growth, an idea that is supported 




 Although less studied, research on centrally located Drosophila presynaptic arbors 
suggest that some mechanisms that control NMJ presynaptic arbor development may be shared. 
In particular, these studies have been performed using the Class IV dendritic arborization (C4da) 
neurons. These multidendritic neurons are nociceptors that mediate larval avoidance of 
potentially harmful stimuli (Hwang et al., 2007). The cell body and dendrites of each C4da 
neuron are located in the larval body wall, with the dendrites fanning out to cover the dorsal 
region of the body wall. These neurons are segmentally repeated, and their axons project to the 
ventral nerve cord (VNC) at regular intervals. Upon reaching the VNC, C4da axon terminals 
branch into anterior, posterior, and contralateral projections that together form a ladder-like 
structure. These axon terminals have previously been shown to be presynaptic terminal arbors 
based on localization of the presynaptic marker synaptotagmin (Kim et al., 2013). This system 
can be manipulated with numerous genetic tools, including mosaic analysis with a repressible 
cell marker (MARCM). Using recombination mediated by a heat-activated flippase at specified 
sites, this technique allows single, homozygous mutant neurons to be labeled in an otherwise 
heterozygous background. This technique is important because it allows single C4da presynaptic 
arbors to be labeled and measured, in addition to allowing investigation of the cell-autonomous 
consequences of loss-of-function of mutations that are lethal in the whole fly. 
 Previous studies that employed the C4da neuron system have shown that Hiw is also an 
important negative regulator of C4da presynaptic arbor growth and that, furthermore, Hiw 
similarly requires Wnd to regulate presynaptic arbor growth (Wang et al., 2013). These findings 
suggest that similar mechanisms may direct presynaptic arbor growth in NMJ axon terminals and 
C4da presynaptic arbors. In this dissertation, I employ the C4da neuron system to study 
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presynaptic arbor growth as it relates to common causes of intellectual disability, Down 
syndrome and Fragile X syndrome. 
1.1.2 The biology of Down syndrome and Fragile X syndrome  
 The most common genetic cause of intellectual disability is Down syndrome, while the 
most common inherited cause of intellectual disability is Fragile X syndrome. Down syndrome 
occurs in 1 in 850 to 1110 live births (Besser et al., 2007). Fragile X syndrome occurs in 
approximately 1 in 3,600 to 4,000 males and 1 in 4,000 to 6,000 females (Turner et al., 1996). 
Down syndrome is caused by the duplication of human chromosome 21 (Jacobs et al., 1959; 
Lejeune et al., 1959) and is typified by delays in growth, characteristic facial features, and 
intellectual disability. In addition, individuals with Down syndrome are at a higher risk of 
developing Alzheimer’s disease, leukemia, congenital heart defects, and thyroid problems. The 
increase in copy-number of chromosome 21 results in the increased expression of a number of 
genes, but which of these are responsible for the diverse traits seen in Down syndrome is still a 
subject of much debate.  
 The early assertion that chromosome band 21q22 is “pathogenic” for Down syndrome 
(Niebuhr, 1974) laid the foundation for the investigation of the biochemical and developmental 
processes by which the characteristics of Down Syndrome arise. Subsequent studies of 
individuals with partial trisomies of chromosome 21 sought to determine which specific regions 
were responsible for particular Down syndrome traits (Epstein et al., 1991; Korenberg et al., 
1994). Early analysis suggested that dosage alteration of an extended region of chromosome 21, 
termed the “Down syndrome critical region” was responsible for the most salient characteristics 
of Down syndrome (Korenberg et al., 1994; Rahmani et al., 1989). However, since human 
trisomies are rare, these phenotypic maps were of low resolution, preventing effective analysis at 
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the required level of single genes (Korbel et al., 2009). More recent analysis using state-of-the-
art genomics and large panels of partial trisomy patients argues against the existence of a single 
critical region in Down syndrome, but suggests the importance of specific genes to particular 
Down syndrome phenotypes (Korbel et al., 2009).  
 Of particular interest to the field of neuroscience is analysis of genes responsible for one 
of the most disabling aspects of Down syndrome, intellectual disability. Intellectual disability 
and atypical central nervous system (CNS) development are characteristic of Down syndrome, 
with patient IQ declining in the first year of life and reaching 25-55 in adulthood (Pennington et 
al., 2003). Down syndrome patients have specific cognitive profiles which include “uneven” 
working memory deficits, wherein verbal short-term memory is more impaired than visuospatial 
short-term memory, impaired long-term explicit verbal and visual object association memory, 
poor expressive and receptive language, and impaired reading ability (Dierssen, 2012). Korbel et 
al. (2009) suggest that there may be a “critical region” for Down syndrome intellectual disability 
phenotypes, which contains several clustered genes including RCAN1, DYRK1A, Down 
syndrome cell adhesion molecule (Dscam), SNF1LK, TMEM1, PFKL, S100β, and possibly 
Amyloid Precursor Protein (APP). Of these, Dscam and APP are of particular interest because of 
their known roles in nervous system development and disease. 
 As predicted based on the increased copy number of the Dscam gene in Down syndrome, 
Dscam is overexpressed in the brains of Down syndrome patients (Saito et al., 2000). Dscam 
levels have also been shown to be elevated in brain tissue of patients with intractable epilepsy, 
where it may contribute to mossy fiber sprouting (Shen et al., 2011). In addition, increased levels 
of Dscam have been seen in postmortem brain tissue of patients with bipolar disorder (Amano et 
al., 2008). Furthermore, Dscam has been shown to bind to Fragile X Mental Retardation Protein 
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(FMRP), and work in Drosophila models of Fragile X syndrome suggests that FMRP controls 
Dscam expression such that Dscam expression level may be increased in Fragile X syndrome. 
 Fragile X syndrome is the most common inherited cause of intellectual disability and is 
considered to be the most common single-gene cause of autism spectrum disorder. Fragile X 
syndrome is caused by the expansion of CGG triplet repeats in the 5’ untranslated region of the 
Fragile X Mental Retardation 1 (FMR1) gene on the X chromosome, which leads to silencing of 
FMRP expression. A CGG copy number of between 6 and 54 repeats is considered normal, 
while Fragile X syndrome patients typically have over 200 repeats (Fu et al., 1991). CGG repeat 
expansion leads the appearance of a chromosomal gap or constriction in metaphase spreads 
which is prone to break under certain conditions, hence the term “Fragile X” (Hecht and 
Sutherland, 1985). Individuals affected with Fragile X syndrome have intellectual disability, 
characteristic facial features, and a predisposition to attention deficit disorder and seizures. 
Furthermore, one-third of individuals with Fragile X syndrome have features of autism spectrum 
disorder, which impairs social interactions and leads to repetitive behaviors and avoidance of eye 
contact (Garber et al., 2008). Postmortem analysis of Fragile X syndrome patient brains reveals 
dense, immature, tortuous dendritic spines (Kaufmann and Moser, 2000). FMRP is a selective 
mRNA binding protein that associates with up to 4% of mammalian mRNAs (Ashley et al., 
1993). FMRP reversibly stalls ribosomes, and hence translation, of its target mRNAs so that 
without FMRP, the levels of many of these proteins are increased (Darnell et al., 2011). 
However, it is not clear which of these proteins are relevant to the development of intellectual 
disability in Fragile X syndrome.  
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1.1.3 Similarities between Down syndrome and Fragile X syndrome 
 Interestingly, several lines of evidence point to shared pathogenic mechanisms between 
Down syndrome and Fragile X syndrome. Importantly, FMRP has been shown to bind to both 
Dscam and APP mRNAs in the mouse brain, which are both increased and implicated in the 
intellectual disability phenotype in Down syndrome (Brown et al., 2001; Darnell et al., 2011). In 
addition, work in our lab and others found that loss of FRMP led to increased Dscam expression 
in Drosophila in vivo (Cvetkovska et al., 2013; Kim et al., 2013). Furthermore, 
hyperconnectivity between neurons has been reported in mouse models of both Down syndrome 
and Fragile X syndrome and in human patients with each of these disorders. In Ts65Dn mice, a 
well-characterized model of Down syndrome, electrophysiological characterization found an 
increase in associational synaptic connections between pyramidal neurons in the CA3 area of the 
hippocampus (Hanson et al., 2007).  
 Similarly, analysis of synaptic connections between layer 5 pyramidal cells in the medial 
prefrontal cortex of FMR1 knockout mice, a mouse model for Fragile X syndrome, revealed an 
increase in connectivity between neighboring pyramidal neurons during development (Testa-
Silva et al., 2012). Similar hyperconnectivity has been observed in human patients with Down 
syndrome and Fragile X syndrome using functional magnetic resonance imaging (fMRI). 
Anderson et al. observed that although Down syndrome patients show simplified brain network 
architecture, neighboring brain areas show increased synchronization as compared to healthy 
controls (Anderson et al., 2013). In autism spectrum disorder patients, several studies have 
reported hyperconnectivity at the whole-brain and subsystems levels, and found that the level of 
hyperconnectivity can predict symptom severity (Supekar et al., 2013; Uddin et al., 2013). 
Although these studies were performed on mixed cohorts of autism spectrum disorder patients, 
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including patients with and without Fragile X syndrome, the fact that hyperconnectivity scores 
are able to predict autism spectrum disorder symptoms in isolated brain scans suggests that 
Fragile X syndrome patients also exhibit hyperconnectivity. 
1.1.4 Scope of this dissertation 
 My dissertation seeks to understand the mechanisms that translate Dscam expression 
level into changes in presynaptic arbor size. Furthermore, it asks whether these mechanisms can 
inform the development of potential therapies for both Down syndrome and Fragile X syndrome. 
It is divided into two parts. The first part reports that Dscam requires a cytoplasmic tyrosine 
kinase, Abelson tyrosine kinase (Abl), to promote presynaptic arbor growth and that 
pharmacologically inhibiting this pathway can rescue the morphological consequences of 
increased Dscam. This work provides proof of principle that knowledge of Dscam signaling 
mechanisms may be able to inform the development of therapies for Down syndrome and Fragile 
X syndrome. The second part of this dissertation reports Dscam and Appl, the Drosophila 
homolog of APP, are mutually required and that Appl furthermore requires Abl to promote 
presynaptic arbor growth. Finally, I show that simultaneous increases in Dscam and Appl act 
synergistically to promote presynaptic arbor size, suggesting that simultaneous increases in 
Dscam and APP in Down syndrome or Fragile X syndrome may lead to more severe 
developmental alterations than an increased levels of either protein alone. 
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 Chapter 2 Dysregulated Dscam levels act through Abelson tyrosine kinase to 
enlarge presynaptic arbors 
2.1 Abstract 
Increased expression of Down Syndrome Cell Adhesion Molecule (Dscam) is implicated in the 
pathogenesis of brain disorders such as Down syndrome (DS) and fragile X syndrome (FXS). 
Here, we show that the cellular defects caused by dysregulated Dscam levels can be ameliorated 
by genetic and pharmacological inhibition of Abelson kinase (Abl) both in Dscam-
overexpressing neurons and in a Drosophila model of Fragile X syndrome. This study offers Abl 
as a potential therapeutic target for treating brain disorders associated with dysregulated Dscam 
expression. 
2.2 Introduction 
 Dscam was first identified because it resides in the so-called Down syndrome “critical 
region”, located on chromosome band 21q22 distal to D21S267 (Yamakawa et al., 1998). Dscam 
is located on chromosome 21q22.2-21q22.3, and shares homolog with genes in the 
Immunoglobulin(Ig)-superfamily. In mammals and Drosophila, Dscam is made up of 24 exons 
that encode, in order from its N-terminus: a signal peptide, nine Ig superfamily domains, four 
fibronectin III domains, one more Ig domain, two more fibronectin III domains, a 
transmembrane domain, and finally a cytoplasmic domain. In addition to Dscam, one other 
Dscam gene is found in humans. Two Dscam homologs are found in mice, while four have been 
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identified in Drosophila melanogaster (Schmucker, 2007). Northern blot analysis revealed that 
Dscam mRNA is expressed in the human fetal brain but not the fetal lung, liver, or kidney. In 
addition, Dscam continues to be expressed in the adult brain at high levels with little expression 
elsewhere in the body (Yamakawa et al., 1998). In mice, Dscam mRNA is ubiquitously 
expressed in embryonic neurons in the developing cortical plate and subplate. Dscam protein 
expression is dynamically regulated during postnatal development in the mouse cortex, with 
peak expression on days P7 to P10, a period characterized by robust neurite outgrowth and 
synaptogenesis (Maynard and Stein, 2012). This expression time-course and pattern positions 
Dscam to play a role in neural development. 
 Dscam also has unique molecular properties that make it an extremely interesting player 
in neural development. When transfected into mouse fibroblasts, human Dscam protein leads to 
enhanced cell adhesion, suggesting that Dscam mediates homophilic intercellular adhesion 
(Agarwala et al., 2000). In addition, analysis of Drosophila Dscam cDNA reveals incredible 
sequence diversity that arises through alternative splicing for alternative exons in the three Ig 
domains as well as the transmembrane domain. Ig2, Ig3, and Ig7 each have 12, 48, and 33 
potential alternative sequences, respectively. Furthermore, the transmembrane domain has 2 
potential splicing variants. This alternative splicing potentially allows for the generation of 
38,016 isoforms. Combining homophilic adhesion with alternative splicing, in vitro studies 
indicate that 95% of Dscam isoforms in Drosophila only bind with a matching copy of the same 
isoform (Wojtowicz et al., 2004; Wojtowicz et al., 2007). Analysis of Dscam mRNA expression 
in Drosophila shows that olfactory, mushroom-body, and photoreceptor neurons each express an 
extensive yet characteristic complement of Dscam isoforms, with each cell expressing several 
splice forms (Neves et al., 2004; Zhan et al., 2004). Interestingly, mammalian Dscam does not 
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encode the same sequence diversity as Drosophila Dscam, but several studies suggest that 
despite this, some core functions may be preserved (Fuerst et al., 2009; Fuerst et al., 2008). 
2.2.1 The role of Dscam in neural development 
 Dscam has been shown to play a role in diverse developmental processes including 
neurite self-recognition (Hughes et al., 2007; Matthews et al., 2007; Soba et al., 2007), synaptic 
specificity and axon targeting (Cvetkovska et al., 2013), and presynaptic arbor growth (Kim et 
al., 2013).  
2.2.2 Dscam diversity and neurite self-recognition 
 Early analysis of Dscam in Drosophila revealed that is alternatively spliced extensively, 
suggesting a role for Dscam in neuronal connectivity and patterning. Indeed, Dscam has since 
been shown to be required for neuronal self-recognition in both axons and dendrites. Neuronal 
self-recognition is important for proper axonal and dendritic connectivity. On the dendritic side 
of the neuron, observation of diverse dendritic arbor morphologies reveals that sister dendrites 
are spaced, spreading out to cover their receptive fields. In the axon, self-recognition is essential 
for the ability of a nascent axonal branch to separate from the parent branch. Self-recognition 
allows the newly formed branch to move away from the parent branch instead of fasciculating 
with the original branch and continuing to both respond to the same signals and to follow the 
same trajectory. But what are the repulsive signals that mediate self-avoidance in dendrites and 
axons? 
 The initial observation that loss of Dscam in Drosophila olfactory receptor neurons 
(ORNs) led to clumped, fasciculated dendrites and reduced dendritic field size raised the 
question of whether Dscam might act as a repulsive signal mediating self-recognition in 
dendrites. Furthermore, analysis of ORNs revealed that overexpression of a single Dscam 
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isoform in two projection neurons that normally exhibited overlapping dendritic fields led to 
dendritic field segregation (Zhu et al., 2006). These results led to the proposal that the array of 
Dscam isoforms displayed on the dendritic surface may provide each neuron with a signal that 
allows it to distinguish its own dendrites from those of neighboring cells. This function is 
supported by results gleaned from another Drosophila system, the larval dendritic arborization 
(da) neurons (Hughes et al., 2007; Matthews et al., 2007; Soba et al., 2007). Da neurons are 
sensory neurons which function in the larval body wall as part of the peripheral nervous system. 
These neurons fall into four classes, each with characteristic dendrite morphology (Grueber et 
al., 2002). Neurons of all classes display self-avoidance but normally coexist with the dendrites 
of neighboring neurons of different types. Loss of Dscam leads to self-avoidance defects in all 
classes of da neurons, causing self-crossing and bundling of dendrites in single Dscam mutant 
clones. This effect is rescued by the overexpression of a single Dscam isoform (Hughes et al., 
2007; Matthews et al., 2007; Soba et al., 2007). Additionally, when a single Dscam isoform is 
overexpressed in all da neurons, strong dendritic avoidance was observed between classes of da 
neurons which usually inhabit the same territory. This suggests that a single Dscam isoform is 
sufficient for self-avoidance, but that Dscam diversity is important to permit the coexistence of 
overlapping dendritic fields within the same territory (Hughes et al., 2007; Matthews et al., 2007; 
Soba et al., 2007). A similar role for Dscam has been described in the mammalian retina, where 
retinal ganglion cells in Dscam mutant mice have fasciculated dendrites in addition to clumped 
cell bodies (Fuerst et al., 2009). This finding suggests a conserved role for Dscam in dendritic 
self-avoidance between invertebrates and mammals. 
 Dscam also mediates self-avoidance in axon development. A central brain structure in 
Drosophila, the mushroom bodies, consists of two lobes which are formed by the stereotyped 
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bifurcation of thousands of axons into a medial and a lateral axon bundle (Ito et al., 1997). Loss 
of Dscam in mushroom body axons prevents segregation of axon branches into the medial 
bundle, such that the two axonal branches will fail to bifurcate and will instead fasciculate and 
continue along the same trajectory (Wang et al., 2002). This effect can be rescued in a single 
mushroom body neuron by overexpressing a single Dscam isoform (Zhan et al., 2004). In 
contrast, reduction of isoform diversity to a single Dscam isoform in all mushroom body neurons 
leads to the formation of a mushroom body that only contains the lateral lobe, a phenotype that is 
indistinguishable from Dscam loss-of-function (Hattori et al., 2007). In addition, reduction 
Dscam diversity from 38,016 possible isoforms to 4,752 isoforms led to mushroom bodies that 
were indistinguishable from those that expressed the full complement of axons (Hattori et al., 
2009). These results suggest that it is important that neighboring mushroom body neurons 
express different Dscam isoforms but that the specific isoforms expressed are unimportant. The 
vast number of Dscam isoforms may function only to ensure that neighboring neurons express 
different isoforms, allowing for robust discrimination between self and other. 
2.2.3 Dscam’s role in synaptic specificity and axon targeting 
 One of the first specific roles for Dscam in Drosophila neural development to be 
described is that of Dscam in the pathfinding of Bolwig’s nerve. Loss of Dscam in this system 
leads to complete nerve mistargeting in 50% of embryos (Schmucker et al., 2000), suggesting 
that Dscam also contributes to proper nervous system development by facilitating the targeting 
for axons to their correct synaptic partners. Indeed, this function is also seen in olfactory 
neurons, where Dscam is required for axonal targeting to the correct glomerulus in the antennal 
lobe, such that loss of Dscam leads defined olfactory neuron types to innervate the wrong 
glomerulus(Hummel et al., 2003). Similarly, Dscam in adult mechanosensory neurons 
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contributes to the establishment of proper axonal connectivity, and loss of Dscam prevents 
directed axon extension toward synaptic targets (Chen et al., 2006). The requirements for Dscam 
diversity in synaptic specificity are different from those of self-recognition. While self-
recognition only requires that neighboring neurons express different isoforms without the 
requirement of specific isoforms, synaptic specificity seems to require not only isoform diversity 
but also specific isoforms. In both olfactory neurons and mechanosensory neurons, Dscam 
isoform diversity is required, as re-expression of randomly chosen Dscam isoform does not 
rescue axonal targeting. In addition, reducing Dscam molecular diversity to 22,176 isoforms also 
led to defects in mechanosensory neuron targeting, suggesting either that a large number of 
alternative isoforms are required or that specific isoforms perform functions that are not 
interchangeable (Chen et al., 2006). Dscam has also been shown to regulate postsynaptic 
specificity at multiple-contact synapses in the Drosophila visual system, where photoreceptor 
highly-stereotyped tetrad synapses. Loss of Dscam in this system leads to incorrect pairing of 
synaptic elements, suggesting that Dscam is responsible for excluding inappropriate partners in 
multiple-contact synapses (Millard et al., 2010). Taken together, these studies suggest that 
Dscam is important for synaptic specificity and that this role may require not only extensive 
Dscam isoform diversity but perhaps also defined subsets of Dscam isoforms. However, future 
research is required to determine whether specific Dscam isoforms are required for proper 
synaptic targeting in distinct neurons. 
2.2.4 Dscam’s role in axonal terminal growth 
 Dscam is also required for proper axon terminal arbor growth. In Drosophila C4da 
neuron axon terminal arbors, loss of Dscam leads to axon terminal arbor truncation, while Dscam 
overexpression leads to increased axon terminal arbor length (Kim et al., 2013). Furthermore, 
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fold change in Dscam expression level shows a nearly linear correlation with fold change in 
presynaptic arbor size. These results suggest that Dscam expression level instructs axon terminal 
arbor length. Unlike Dscam’s roles in self-avoidance and synaptic specificity however, the 
instruction of presynaptic arbor size by Dscam appears to be isoform diversity-independent. In 
support of this idea, single C4da neuron that express only a single Dscam isoform (though at the 
same level as wildtype Dscam) have defects in presynaptic arbor patterning but normal 
presynaptic arbor length (Kim et al., 2013). Furthermore, randomly selected Dscam isoforms are 
equally capable of promoting presynaptic arbor growth when overexpressed in C4da neurons. 
These results suggest a model wherein Dscam’s roles in synaptic targeting and presynaptic arbor 
size control are separable, with the former controlled by isoform diversity and the later 
controlled by Dscam expression level. Two convergent mechanisms control Dscam expression at 
the level of protein translation: one involving the dual leucine zipper kinase Wnd that requires 
the 3’ untranslated region of Dscam (Kim et al., 2013) and another involving FMRP (Cvetkovska 
et al., 2013) that acts on the Dscam coding region (Kim et al., 2013). These two mechanisms 
work in opposite directions, such increased Wnd expression leads to increased Dscam expression 
while loss of FMRP leads to increased Dscam expression. Increased Dscam expression in FMRP 
mutants suggests that Dscam expression level may be higher in Fragile X syndrome, as it is in 
Down syndrome. 
2.3 Materials and Methods 
2.3.1 Fly strains  
abl
1
 (Gertler et al., 1989), abl
4
 (Bennett and Hoffmann, 1992) ppk-Gal4 (Kuo et al., 2005), UAS-
Dscam[3.36.25.2]::GFP (Yu et al., 2009), UAS-Abl, UAS-BCR-Abl, UAS-Abl-K417N (Wills et 
al., 1999), and dFMRP
Δ50M
 (Zhang et al., 2001) were used in this study.  
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2.3.2 DNA constructs and generation of transgenic flies 
To generate pUASTattB-Abl::Myc for expression in S2 cells, the coding region of Abl was 
recovered from UAS-Abl transgenic flies by PCR, subcloned into pUASTattB-Myc by using the 
InFusion cloning system following manufacturer’s protocol (Clontech, Mountain View, 
California). We generated pUASTattB-Abl-K417N::Myc by PCR mutagenesis as previously 
described (O’Donnell and Bashaw, 2013) from pUASTattB-Abl::Myc. UAS-
Dscam[3.36.25.2]::GFP was previously generated as described (Kim et al., 2013). To generate 
UAS-DscamΔCyto, the Dscam coding region was digested with SstI and ligated with the GFP 
cDNA.  
 To generate UAS-Pickles2.31, the Pickles2.31 coding region was subcloned from 
pCAGGS-Pickles2.31 into pUASTattB using the InFusion cloning system following the 
manufacturer’s protocol (Clontech). Transgenic flies carrying UAS-DscamΔCyto, UAS-
Abl::Myc, and UAS-Pickles2.31 were generated by germline transformation with support from 
BestGene, Inc. Pickles2.31 was generously provided by Dr. Yusuke Ohba at RIKEN Brain 
Science Institute (Mizutani et al., 2010). 
2.3.3 Labeling presynaptic terminals using MARCM 







, and overexpressing Dscam[3.36.25.2]::GFP as previously described (Kim et al., 
2013).  
2.3.4 Immunostaining and imaging  
Immunostaining of third-instar larvae was accomplished as previously described (Ye et al., 
2011). Antibodies used include chicken anti-GFP (Aves, Tigard, Oregon) and rabbit anti-RFP 
(Rockland, Limerick, Pennsylvania). Samples were dehydrated and mounted with DPX 
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mounting media (Electron Microscopy Sciences, Hatfield, Pennsylvania). Confocal imaging was 
completed with a Leica SP5 confocal system equipped with a resonant scanner and 63× oil-
immersion lens (NA = 1.40). Images were collected and quantified as previously described (Kim 
et al., 2013).  
2.3.5 S2 cell culture and transfection  
Drosophila S2 cells were maintained in Drosophila Schneider’s medium supplemented with 10% 
fetal bovine serum at 25˚C in a humidified chamber. Cells were transfected with indicated DNA 
constructs together with tubulin-Gal4 (Lee and Luo, 2001) by using Lipofectamine 2000 (Life 
Technologies, Grand Island, New York) according to manufacturer’s protocol.  
2.3.6 Co-immunoprecipitation and Western blotting  
To perform co-immunoprecipitation, transfected S2 cells were harvested and lysed on ice with 
lysis buffer (50 mM Tris-HCl/pH 7.4, 150 mM NaCl, 2 mM sodium vanadate, 10 mM sodium 
fluoride, 1% Triton X-100, 10% glycerol, 10 mM imidazole and 0.5 mM phenylmethylsulfonyl 
fluoride). Lysates were centrifuged for 15 min at 20,000×g, 4˚C and the resulting supernatant 
was incubated with Protein A/G PLUS-Agarose beads (Santa Cruz Biotechnology, Paso Robles, 
California) conjugated to mouse monoclonal anti-GFP clone 20 (Sigma-Aldrich, St. Louis, 
Missouri) for 4 hr at 4˚C. After washing once with lysis buffer, twice with lysis buffer containing 
0.1% deoxycholate, and 3 times with lysis buffer lacking Triton X-100, the immunoprecipitates 
and total lysates were resolved on 7.5% SDS-PAGE gels followed by western blot analysis as 
previously described (Kim et al., 2013). Primary antibodies used in western blotting were mouse 
monoclonal anti-tubulin (Sigma), mouse anti-Myc (Sigma-Aldrich), mouse monoclonal anti-
Aequorea Victoria GFP JL-8 (Clontech), and rabbit anti-phospho-Tyr412-c-Abl (Cell Signaling, 
Beverly, Massachusetts).  
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2.3.7 In vivo Abl activity assay with Pickles2.31 
To assay in vivo Abl activation, UAS-Pickles2.31 was expressed specifically in C4da neurons 
using ppkGal4 along with other UAS transgenes. The CNS was dissected from third-instar larvae 
into ice-cold PBS with 2 mM sodium vanadate (∼100 per experimental condition). After a brief 
centrifugation, larval CNSs were transferred into lysis buffer as described above in 
immunoprecipitation and western blotting. Cells were disrupted using a pestle followed by brief 
sonication. Immunoprecipitation and western blotting of Pickles2.31 was then accomplished as 
described above. Primary antibodies used were rabbit anti-eGFP (a gift from Dr Yang Hong) and 
rabbit anti-phospho-Tyr 207-CrkL (Cell Signaling).  
2.3.8 Drug treatment of Drosophila larvae and S2 cells  
Nilotinib (Abcam, United Kingdom) and bafetinib (ApexBio Technology, Houston, Texas) were 
dissolved in dimethyl sulfoxide (DMSO) at 94 mM and 50 mM, respectively, as stock solutions 
before adding to S2 cells or fly food. S2 cells transfected with Abl::Myc were treated with either 
5 μM nilotinib or the same volume of DMSO as a vehicle control for 6 hr before harvested and 
subjected to western blot analysis. Nilotinib and bafetinib were administered to larvae by rearing 
the larvae on standard corn meal food containing different concentrations of the drugs. The 
highest concentrations that did not affect overall larval development were used. Fly viability on 
nilotinib treatment was performed by counting the number of adult flies. Seven virgin female and 
seven male flies were crossed and transferred to standard corn meal food containing either 380 
μM nilotinib or the same volume of DMSO (0.4% final concentration). Embryos were collected 
for 24 hr and allowed to develop. Eclosed adult flies were counted on a daily basis. The 
MARCM technique was used to generate and visualize mutant single C4da neurons as described 
above except that Drosophila embryos were collected and raised for 4 days on standard corn 
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meal food containing either 380 μM nilotinib, 125 μM Bafetinib, or 0.4% DMSO. Sample 
preparation, imaging, and quantification were then completed as described above.  
2.3.9 Colocalization analysis 
Colocalization of Dscam and Abl was quantified with Manders’ Correlation Coefficients using 
the Just Another Colocalization Plugin (JACoP) (Bolte and Cordelieres, 2006) in ImageJ. Images 
were analyzed in three dimensions. Manders’ Correlation Coefficients vary between 0 and 1, 
with 0 representing no overlap between images and 1 representing complete colocalization. M1 
and M2 describe the overlap of each channel with the other (Bolte and Cordelieres, 2006). M1 
presents a measure of the fraction of Abl::Myc that overlaps Dscam(ΔCyto)::GFP, while M2 
presents a measure of the fraction of Dscam(ΔCyto)::GFP that overlaps Abl::myc.  
2.3.10 Statistical analysis 
Two-way student’s t- test was used for statistical analysis. *: p < 0.05; **: p < 0.01; ***: p < 
0.001; ****: p < 0.0001; ns: not significant. 
2.4 Results 
2.4.1 Abl is sufficient to promote presynaptic arbor growth in C4da neurons 
 To delineate the molecular mechanisms of Dscam signaling in axon terminal arbor 
development we took advantage of the Drosophila C4da neuron system, which has previously 
been used to study the effects of Dscam expression level during development (Hughes et al., 
2007; Kim et al., 2013; Matthews et al., 2007; Soba et al., 2007). From tests of candidate genes 
that potentially mediate Dscam function, including focal adhesion kinase, proto-oncogene 
tyrosine-protein kinase Fyn, p21 Activated Kinase, Ras homolog gene family member A, and 
Abelson tyrosine kinase (Abl), we identified Abl as a key molecule mediating Dscam’s functions 
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in presynaptic terminal growth. I first asked whether Abl is sufficient to promote presynaptic 
terminal arbor growth in C4da neurons. Consistent with a previous study performed in 
Drosophila adult CNS neurons (Leyssen et al., 2005), overexpression of Abl in C4da neurons 
caused significant overgrowth of the presynaptic terminals (Figure 2.1 a,b,e). Since Abl is known 
to have both kinase-dependent and kinase-independent functions (Henkemeyer et al., 1990; 
Schwartzberg et al., 1991; Tybulewicz et al., 1991), I tested whether expression of a kinase-dead 
form of Abl, Abl-K417N (Henkemeyer et al., 1990; Wills et al., 1999), could promote 
presynaptic terminal growth. I found that C4da presynaptic terminals overexpressing Abl-K417N 
were indistinguishable from wild-type (Figure 2.1 d,e), indicating that Abl kinase activity is 
required. Based on this result, I hypothesized that if presynaptic terminal growth is dependent on 
Abl kinase activation, overexpression of a constitutively active form of Abl should lead a greater 
increase in presynaptic terminal growth than Abl alone. One well-known constitutively active 
form of Abl is BCR-Abl, which results from reciprocal translocation between chromosomes 9 
and 22 in human patients with chronic myeloid leukemia. This translocation leads to the 
juxtaposition of the Abl gene with the Breakpoint Cluster Region (BCR) gene, resulting in a 
fusion protein that has constitutive Abl kinase activity (Rowley, 1973). Consistent with the idea 
that Abl kinase activation is important, overexpression of constitutively active BCR-Abl led to 
extremely exuberant presynaptic terminal overgrowth (Figure 2.1 c,e). Taken together, these 
results suggest that Abl is sufficient to promote presynaptic terminal growth and that the extent 




2.4.2 Dscam requires Abl to promote presynaptic terminal growth 
 Since overexpression of Abl increases presynaptic terminal growth, similar to Dscam, I 
next tested whether Dscam requires Abl to instruct presynaptic terminal growth. For this, I used 
the mosaic analysis with a repressible cell marker (MARCM) technique to overexpress Dscam in 
abl
1
 mutant C4da neurons (Lee and Luo, 2001) and assessed presynaptic terminal length. 
Importantly, I was able to investigate the cell-autonomous consequences of both Dscam 
overexpression and abl loss-of-function using this technique. I found that although Dscam 
overexpression led to significantly (150%) longer presynaptic terminals than wildtype clones 
(Figure 2.1 f,g,o), abl
1
 mutant clones that overexpressed Dscam did not differ in length from abl
1
 
mutant clones (Figure 2.1 h,i,o). Presynaptic terminal length was also subtly but significantly 
shorter in abl
1
 mutant clones compared to wild-type controls (Figure 2.1 i,o). A different loss-of-
function allele of abl, abl
4
, exhibited similar effects on the presynaptic overgrowth caused by 
Dscam overexpression (Figure 2.1 j,k,o), confirming that loss of abl function is responsible for 
blocking the presynaptic phenotypes caused by increased Dscam levels. Consistent with the idea 
that Abl is not involved in trafficking Dscam to the presynaptic arbors, abl loss-of-function 
mutations did not affect the expression of the Dscam transgenes in the C4da cell body or 
presynaptic terminals (Figure 2.2).  
 As a further proof-of-concept, I asked whether loss of abl could mitigate the effects of 
dysregulated Dscam levels without utilizing Dscam transgenes. Fragile X syndrome is caused by 
an absence of FMRP (Kremer et al., 1991), and is modeled in Drosophila using loss-of-function 
mutants for the Drosophila homolog of FMR1, dFMRP (Dockendorff et al., 2002; Zhang et al., 
2001). It has previously been shown that FMRP binds to Dscam mRNA in both mammals and 
Drosophila (Cvetkovska et al., 2013; Darnell et al., 2011; Kim et al., 2013) and that dFMRP 
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represses Dscam expression to control presynaptic terminal growth, so that dFMRP mutants 
exhibit increased presynaptic terminal length in C4da neurons (Kim et al., 2013). Strikingly, loss 
of only a single copy of abl significantly rescued presynaptic terminal length to wild-type levels 
(Figure 2.1 l–n,p). These results suggest that Abl is required for Dscam to instruct presynaptic 
terminal growth.  
2.4.3 Abl is not required for Dscam’s role in dendritic self-avoidance 
 An important function of Dscam in neuronal development is mediating self-avoidance 
between neurites of the same neuron (Zipursky and Grueber, 2013). Abl does not seem to be 
required by Dscam for either dendrite growth, as loss of Abl did not significantly alter dendritic 
length in C4da neurons, or for dendritic self-avoidance in C4da neurons, as no dendritic 
fasciculation or clumping was observed in abl mutant neurons (Figure 2.3). To further test 
whether abl is required for dendritic self-avoidance, I used a previously described ectopic 
dendritic avoidance assay. In the Drosophila larval peripheral nervous system, the dendrites of 
dendritic arborization (da) neurons project across the body wall and can be placed into four 
morphologically-distinct classes, I-IV. While sister dendrites of all da neurons show self-
avoidance, the dendrites of neighboring neurons of different classes overlap extensively (Grueber 
et al., 2002). Previous studies have shown that all classes of da neurons require Dscam for self-
avoidance. Overexpression of a single Dscam isoform in two neurons whose dendritic fields 
normally overlap, class I neuron vpda and class III neuron v’pda, causes their dendritic fields to 
segregate (Hattori et al., 2007; Hughes et al., 2007; Matthews et al., 2007). These results suggest 
that Dscam is both necessary and sufficient to cause dendritic self-avoidance in da neurons. 
Consistent with previous reports, I found that the dendritic territories of wildtype class I vpda 
and class III v’pda neurons overlapped extensively, while overexpression of a single form of 
26 
 
Dscam caused their dendritic territories to segregate as assessed by counting dendritic crossings 
of class I and class III dendrites (Figure 2.4 a,b,d). In addition, I found that loss of abl did not 
compromise the ectopic avoidance caused by overexpressing Dscam in these distinct types of da 
neurons (Figure 2.4 c,d). This suggests a divergence in Dscam signaling between presynaptic 
terminal and dendritic branch development. Taken together, these results indicate that Abl is 
specifically required for Dscam-mediated presynaptic terminal growth.  
2.4.4 Dscam and Abl bind through the Dscam cytoplasmic domain in culture and in vivo 
 Next, I asked how Abl might mediate Dscam signaling. Abl is a cytoplasmic tyrosine 
kinase with high sequence conservation between Drosophila and mammals. Abl contains an SH3 
domain, SH2 domain, and a kinase domain. In its inactivate state, these SH3 and SH2 domains 
bind in a closed conformation to an SH3-binding site in the Abl linker domain and to the Abl 
kinase domain, respectively. However, intercellular binding to SH3- and SH2-binding sites on 
other molecules, including the cytoplasmic domain of membrane receptors, moves Abl into an 
active conformation, which in turn leads to catalytic activation of Abl (Bradley and Koleske, 
2009). To test whether Abl might be binding to the cytoplasmic domain of Dscam, we created a 
Dscam transgene that lacks most of the cytoplasmic domain, deleting the last 877 base pairs of 
the intracellular domain including half of exon 18 and all of exons 19 through 23 (DscamΔCyto). 
In contrast to the exuberant presynaptic terminal overgrowth caused by Dscam overexpression in 
C4da neurons (Figure 2.5 a, middle), overexpressing DscamΔCyto did not cause presynaptic 
terminal overgrowth (Figure 2.5 a, bottom). DscamΔCyto was trafficked to the axon terminals 
and expressed at a similar level to full length Dscam (Figure 2.6). These results suggest that the 
cytoplasmic domain is required for Dscam to instruct presynaptic terminal growth. I then asked 
whether Dscam and Abl physically interact with each other through the Dscam cytoplasmic 
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domain. I found that Dscam and Abl proteins co-immunoprecipitated from transfected 
Drosophila Schneider 2 (S2) cells expressing these two proteins (Figure 2.5 b, second lane from 
right). In contrast, DscamΔCyto did not co-immunoprecipitate Abl (Figure 2.5 b, furthest right 
lane). These results suggest that Dscam and Abl proteins form a complex through Dscam’s 
cytoplasmic domain.  
 Next, to test the in vivo interaction of Dscam and Abl in presynaptic terminals 
specifically, I determined whether Abl localization in presynaptic terminals was altered by the 
expression of Dscam or DscamΔCyto (Figure 2.5 c). When expressed alone or with 
DscamΔCyto::GFP, Abl::Myc was diffusely distributed in the presynaptic terminals, showing 
scant colocalization with DscamΔCyto::GFP (Figure 2.5 c, middle and bottom). However, when 
expressed with Dscam::GFP, Abl::Myc became more punctate and clearly colocalized with 
Dscam::GFP (Figure 2.5 c, top). I used Manders’ Correlation Coefficients to quantify the 
colocalization of Dscam::GFP and Abl::Myc. Colocalization analysis revealed a significant 
increase in both M1 and M2 (Figure 2.5 c, bottom right) when Abl::Myc was coexpressed with 
Dscam::GFP as compared to when Abl::Myc was coexpressed with DscamΔCyto::GFP, where 
M1 represents the fraction of Abl that overlaps with Dscam, and M2 represents the fraction of 
Dscam that overlaps with Abl. These findings support the idea that Abl and Dscam interact in 
presynaptic terminals in vivo.  
2.4.5 Dscam activates Abl in culture and in C4da presynaptic arbors in vivo 
 Do increased Dscam levels activate Abl kinase? In mammals, autophosphorylation of Abl 
at tyrosines 245 and 412 (Y245 and Y412) stabilizes the active conformation of the kinase 
(Brasher and Van Etten, 2000; Tanis et al., 2003). As a result, phospho-specific antibodies raised 
against Y412 have been employed to detect active Abl kinases (Brasher and Van Etten, 2000). 
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Since Abl is highly conserved between Drosophila and mammals, this approach has been used 
successfully to recognize the phosphorylation of the corresponding tyrosines (Y539/522) in 
Drosophila as an assay for Abl kinase activation (Stevens et al., 2008). Since the ability of Abl to 
instruct presynaptic terminal growth relies on Abl kinase activity, I tested whether Dscam 
activates Abl using a phosho-Y412-Abl (p-Abl) antibody. I found that Abl kinase activation was 
significantly increased (2.6 fold) when Abl and Dscam were co-expressed in S2 cells (Figure 2.7 
a). Furthermore, unlike wild-type Dscam, DscamΔCyto did not increase Abl kinase activation. In 
fact, it appears to act as a dominant-negative, as Abl activity was significantly decreased from 
control (Figure 2.7 a, right). As a negative control, no signal was detected when the kinase-dead 
Abl-K417N was blotted with p-Abl antibody in the same assay, suggesting that our assay 
specifically reported Abl activation (Figure 2.8). These results suggest that Dscam enhances Abl 
kinase activity.  
 To investigate whether the same is true in presynaptic terminals in vivo, I devised a novel 
method of reporting Abl activation specifically in C4da presynaptic terminals. To achieve this, I 
used a previously described probe that reports Abl activity, Phosphorylation indicator of CrkL en 
substrate number 2.31 (Pickles2.31) (Mizutani et al., 2010). Designed as a Förster resonance 
energy transfer (FRET) probe, Pickles2.31 is composed of a fragment of a characteristic Abl 
substrate, CrkL, sandwiched between the fluorescent proteins Venus and enhanced CFP (ECFP) 
(Figure 2.7 b). It has previously been reported that activated Abl phosphorylates Pickles2.31 on 
the Y207 residue of the CrkL fragment, which can be detected with an antibody against CrkL-
phospho-Y207 (p-CrkL) (Mizutani et al., 2010). After expressing Pickles2.31 specifically in 
C4da neurons with the ppk-Gal4 driver, I dissected the larval CNS and immunoprecipitated 
Pickles2.31 from the lysates. Since the cell bodies of C4da neurons reside in the body wall, using 
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only the larval CNS allowed us to monitor Pickles2.31 phosphorylation only in the C4da neuron 
presynaptic terminals (Figure 2.7 c). Consistent with the notion that Pickles2.31 is an Abl 
activity indicator, overexpression of BCR-Abl led to a robust increase in phospho-Y207 levels as 
compared to the control. Furthermore, I found that overexpression of Dscam in C4da neurons led 
to an increase in Y207 phosphorylation of Pickles2.31 in the presynaptic terminals, while 
overexpression of DscamΔCyto was indistinguishable from control (mCD8-mRFP) (Figure 2.7 
d). These results suggest that Dscam activates Abl both in culture and in C4da presynaptic 
terminals in vivo, and that this activation requires the cytoplasmic domain of Dscam.  
2.4.6 Inhibition of Abl with tyrosine kinase inhibitors mitigates the consequences of 
increased Dscam expression in C4da presynaptic arbors 
 These results raised the interesting possibility that targeting Abl might be a viable therapy 
for brain disorders caused by increased Dscam expression. Abl is a well-established target for 
treating chronic myeloid leukemia, and there are multiple Abl inhibitors that are approved by the 
US Food and Drug Administration (FDA). As a proof-of-concept experiment, we attempted to 
rescue the developmental defects caused by Dscam overexpression using Abl inhibitors. We first 
tested nilotinib, which is an FDA-approved second-generation Abl kinase inhibitor that can cross 
the blood–brain barrier (Weisberg et al., 2005) (Hebron et al., 2013). Using cultured S2 cells 
overexpressing Abl, we found that nilotinib robustly inhibited Drosophila Abl (Figure 2.9 a). 
Based on these results, we tested whether administration of nilotinib to developing larvae could 
rescue the effects of increased Dscam expression in C4da presynaptic terminals in vivo. To do 
this, we performed MARCM to visualize single C4da neurons in animals fed nilotinib or vehicle 
and assessed presynaptic terminal length. While overexpression of Dscam caused increased 
(152%) presynaptic terminal length in animals fed vehicle (Figure 2.9 b–d), the effect was 
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significantly rescued (to 115% of control) by feeding the animals with nilotinib (Figure 2.9 b,e). 
Consistent with the idea that these effects were due to inhibition of Abl activity rather than a 
reduction in Dscam expression, nilotinib did not change the expression of the Dscam-GFP 
transgene (Figure 2.10). Administration of nilotinib to developing larvae did not adversely affect 
overall development and neuronal growth. At the dose we used, nilotinib did not cause changes 
in presynaptic terminal growth (Figure 2.9 f) or dendritic growth (Figure 2.11 a,b) in wild-type 
larvae. Moreover, it did not impact the number of adults that eclosed or the dynamics of eclosion 
when compared to vehicle-fed flies (Figure 2.11 c,d). Although frequently used to inhibit 
pathological increases in Abl activity in patients, nilotinib is known to have several off-targets, 
including c-Kit, PDGFR, Arg, NQ02, and DDR1 (Hantschel et al., 2008). Consistent with the 
idea that nilotinib acts on Abl rather than on an off-target molecule to rescue presynaptic 
terminal growth, administering nilotinib to larvae overexpressing Dscam in abl
1
 mutant single 
C4da neurons did not lead to a further decrease in presynaptic terminal length when compared to 
vehicle-fed control (Figure 2.21 c,d). To further rule out the possibility that the observed rescue 
of presynaptic terminal length by nilotinib was the result of an off-target effect, we tested 
bafetinib, another Abl inhibitor with non-overlapping off-targets, Fyn and Lyn (Kimura et al., 
2005). Bafetinib has also been shown to cross the blood-brain barrier (Santos et al., 2010). Like 
nilotinib, administration of bafetinib to Dscam-overexpressing larvae led to a significant 
decrease in presynaptic terminal length (Figure 2.12 a,b,f,g) without changing the expression of 
the Dscam transgene (Figure 2.10 b). Bafetinib alone did not change presynaptic terminal length 
in wild-type larvae when compared to wild-type larvae fed vehicle (Figure 2.12 egG). Taken 
together, these results suggest that pharmacological inhibition of Abl mitigates the consequences 
of increased Dscam signaling in vivo. We next sought to test the efficacy of nilotinib treatment 
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in a model of a disease associated with dysregulated Dscam expression, Fragile X syndrome. 
Thus, we tested whether administration of nilotinib could rescue the presynaptic overgrowth 
caused by increased Dscam expression in dFMRP mutants. We found that, while dFMRP 
mutants fed vehicle showed a significant increase (130%) in presynaptic terminal length (Figure 
2.9 b,g), administration of nilotinib to dFMRP mutants almost completely rescued (to 103% of 
control) the exuberant presynaptic terminal growth to wild-type levels (Figure 2.9 b,h). These 
results suggest that pharmacological inhibition of Abl kinase is effective for mitigating the 
effects of increased Dscam level in an in vivo model of Fragile X syndrome.  
2.5 Discussion 
 In this study, I show that Dscam requires Abl to promote presynaptic terminal growth in 
vivo and that the binding of Abl to the Dscam cytoplasmic domain leads to Abl kinase 
activation. Furthermore, we show that treating Drosophila larvae with Abl inhibitors rescues the 
developmental defects caused by increased Dscam levels in vivo in both Dscam-overexpressing 
neurons and disease-relevant models. 
 Although Abl has previously been shown to promote axon arborization in Drosophila 
(Leyssen et al., 2005), this was the first study reporting that Abl promotes presynaptic terminal 
arbor growth in C4da neurons. Interestingly, I found that although overexpression of wildtype 
Abl increased presynaptic terminal length, this effect was mild. This may suggest that even when 
Abl expression is increased, Abl activation remains tightly controlled. The overexpression of 
BCR-Abl led to extremely increased presynaptic terminal growth, to a similar extent to that seen 
when Dscam is overexpressed in all C4da neurons. Consistent with our findings, this suggests 
that Dscam may activate Abl, so that only overexpression of activated Abl mirrors the Dscam 
overexpression phenotype.  
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 In addition, although Dscam and BCR-Abl overexpression lead to exuberant increases in 
presynaptic arbor growth, the phenotypes of each of these treatments appear subtly different. To 
the trained eye, it is clear that overexpression of BCR-Abl leads to an increased number of 
connectives, but that these connectives are still relatively well fasciculated. In contrast, although 
overexpression of Dscam also leads to an increased number of connectives, the connectives are 
not well fasciculated and thus spread out to cover a wider space, making each connective appear 
wider and narrowing the space in the middle of the axon ladder between the contralateral 
connective. I speculate that this “avoidance” phenotype in Dscam overexpression results from 
Dscam’s known function in neuronal self-avoidance, which has previously been reported in both 
dendrites and axons. Since a single Dscam isoform was expressed in all C4da neurons, 
neighboring presynaptic terminals avoid one another, resulting in wider and less fasciculated 
connectives. I hypothesize that if Dscam expression were increased in C4da neurons without 
altering the relative levels of each Dscam isoform, the phenotype would closely resemble that of 
overexpression BCR-Abl. 
 I show that Dscam requires Abl to instruct presynaptic terminal growth. However, 
although loss of Dscam has been shown to result in severely truncated presynaptic terminals 
(Kim et al., 2013), loss of abl only leads to a subtle, though significant, decrease in presynaptic 
terminal length. This is counterintuitive because if Dscam’s effect in presynaptic terminal growth 
is mediated entirely through Abl, one would expect Dscam and abl loss-of-function phenotypes 
to be identical. This subtle effect of abl loss-of-function is likely to be explained by perdurance 
and maternal contribution. Using the MARCM system, abl function will be completely lost in a 
MARCM clone upon its final division. However, Abl protein present before this division may 
persist, a phenomenon known as perdurance. Furthermore, Drosophila embryos that have no 
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zygotic abl but whose mothers are heterozygous for abl mutations live until the late larval stage. 
In contrast, Drosophila embryos that lack both maternal and zygotic abl die before the 
completion of embryogenesis, suggesting that Abl mRNA is maternally contributed (Bennett and 





 MARCM results are probably due to a combination of both perdurance and maternal 
contribution. A future experiment that would confirm this hypothesis is to generate Drosophila 
embryos that lack both zygotic and maternal abl (Chou and Perrimon, 1996) and then examine 
C4da presynaptic terminals using ppk-eGFP.  
 We show here that increased Dscam expression leads to increased Abl activation both in 
culture and in vivo. The observation that DscamΔCyto may act as a dominant negative is 
intriguing, as the mechanism by which this would occur in unclear. This suggests the influence 
of other molecular partners and could be explained if Dscam works in concert with another 
protein that interacts with Dscam via the Dscam extracellular domain. In this scenario, loss of the 
Dscam cytoplasmic domain would render Dscam incapable of activating Abl, but would not 
change its interactions with its other partner through the extracellular domain. Therefore, 
DscamΔCyto would bind up a majority of the functional partner, leaving the remaining wildtype 
Dscam with fewer opportunities to interact. 
 Our in vivo Abl activation assay with Pickles2.31 represents the first time, to our 
knowledge, that Abl activation has been assayed in a cell-type-specific manner in Drosophila in 
vivo. Moreover, this assay is unique in that it allows assessment of Abl activation in a cell-
compartment-specific manner – axon terminals in this case. The success of this assay also 
demonstrates that mammalian CrkL is phosphorylated by Drosophila Abl, further evidence that 
Abl function is highly conserved between Drosophila and mammalian systems. Future studies 
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could extend this assay to develop an in vivo FRET assay that directly measures FRET 
efficiency in C4da presynaptic arbors. 
 Furthermore, in the course of our in vivo Abl activity assay using Pickles2.31, we found 
that the phospho-CrkL antibody we used also recognizes a phosphorylated tyrosine on the 
Dscam cytoplasmic domain. Importantly, this site is only phosphorylated when Dscam is co-
expressed with Abl, so that no signal is detected at the site of the Dscam band if Dscam is 
expressed without Abl. This suggests that Abl phosphorylates a site on Dscam. Furthermore, we 
found that when Abl was co-expressed with a Dscam transgene with all of the cytoplasmic 
tyrosines mutated to phenylalanine (Dscam-AllF), phospho-Dscam staining was no longer 
visible, indicating that Abl phosphorylates one or more tyrosines in the Dscam cytoplasmic 
domain (Figure 2.13). This suggests a mechanism wherein Abl binds to Dscam via an SH3-
binding site in the Dscam cytoplasmic domain and then phosphorylates a tyrosine, creating an 
SH2-binding site. Abl will, in turn, may then bind to the SH2-binding site that has been created, 
leading to increased Abl activation. Further research is required to test this hypothesis, but 
detailed knowledge of the sites and mechanisms that allow Dscam to activate Abl may open the 
door for rationally designed therapeutics that disrupt Dscam-Abl binding. 
 Finally, our results suggest that Abl inhibition with FDA-approved tyrosine kinase 
inhibitors can block morphological changes caused by increased Dscam expression. This result is 
proof of the concept that disrupting Dscam signaling might prove therapeutic for disorders in 
which Dscam signaling is dysregulated, like Down syndrome or Fragile X syndrome. Our results 
suggest that the tyrosine kinase inhibitors we tested are acting through inhibition of Abl, as two 
such drugs with non-overlapping off-targets rescued presynaptic terminal length in Drosophila 
larvae that overexpressed Dscam. Importantly, feeding tyrosine kinase inhibitors to wild-type 
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flies did not lead to decreases in presynaptic terminal length when compared to flies fed vehicle. 
This result is significant because it suggests that this drug treatment is targeting pathogenic 
activation of Abl and does not interfere with development of presynaptic terminals in general. 
This result may be explained by two different hypotheses. On one hand, tyrosine kinase 
inhibitors may inhibit some Abl but not all Abl. This means that a low level of Abl activation is 
maintained in the treated flies, allowing Abl to perform its normal physiological functions. On 
the other hand, Abl activity may not play an important role in the normal development of 
presynaptic terminals, so that inhibiting Abl during development would not affect the final length 
of presynaptic terminals. We favor the former explanation, as the later does not fit with our 
observation that loss of abl leads to significantly shorter presynaptic terminals, nor does it 
explain the axonal truncation previously reported in Drosophila embryos lacking both maternal 
and zygotic Abl (Grevengoed et al., 2001). 
 The results of this study present the first signaling mechanism of Dscam in presynaptic 
terminal growth. It is hoped that these findings will open the door for discovery of more detailed 




Figure 2.1 Dscam requires Abl to promote presynaptic terminal growth.  
(a-d) Abl is sufficient to cause axon terminal overgrowth in C4da neurons. Transgenes were 
expressed with a C4da neuron-specific Gal4 driver, ppk-Gal4, and presynaptic terminals were 
visualized with membrane monomeric RFP (mRFP) transgene. Overexpression of Abl (b) leads 
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to a modest increase in presynaptic terminal growth when compared to control (a). 
Overexpression of constitutively active BCR-Abl (d) leads to extremely robust increased 
presynaptic terminal growth, while overexpression of kinase-dead Abl-K417N (c) is 
indistinguishable from control. Scale bars are 5 μm. (e-j) Abl is required in C4da neurons for 
Dscam to instruct presynaptic terminal growth. The MARCM technique was used to generate 
and visualize single mutant C4da neurons. While overexpression of Dscam::GFP (f) in single 
C4da presynaptic terminals leads to increased length when compared to control (e), 
overexpression of Dscam in abl1 mutant neurons leads to presynaptic terminal lengths that are 
indistinguishable from abl1 mutant neurons (g). Similarly, overexpression of Dscam in abl4 
mutant neurons (j) does not significantly change presynaptic terminal length when compared to 
abl4 mutant neurons (i). Scale bar is 10 μm. (k) Quantification of the presynaptic arbor length in 





Figure 2.2 Loss of Abl does not affect Dscam-GFP expression level.  
(a) Example images of C4da neuron cell bodies (white arrowheads) in control (left) or abl
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homozygous mutant (right) animals. Upper images show merged signals of cCD8::mRFP and 
Dscam::GFP, while lower images show Dscam-GFP alone. Scale bar is 5 µm. (b) Quantification 
of the relative intensity of Dscam::GFP fluorescence normalized to CD8-mRFP. Sample number 




Figure 2.3 Loss of abl does not affect C4da dendritic length or morphology.  
Representative images of control (a) and abl1 mutant C4da neuron clones (b). The average total 






Figure 2.4 The single Dscam isoform-induced ectopic repulsion between class I and class III 
dendrites does not require Abl.  
The dendritic field of the class I da neuron vpda (traced in magenta) normally overlaps 
extensively with that of the class III da neuron v’pda (traced in cyan) (a). When a transgene 
expressing a single Dscam isoform is overexpressed in both neurons, their dendritic fields 
segregate (b), exhibiting an ectopic repulsion. The expression of the same Dscam transgene in 
abl
1
 neurons also leads to ectopic repulsion. Original background images show the pan-neuronal 
marker labeled with anti-Horseradish-peroxidase antibody (red) and Dscam::GFP transgene 
expression (green). (d) Quantification of the number of dendritic branch crossing. Sample 





Figure 2.5 Dscam binds to Abl through its cytoplasmic domain. 
(a) The cytoplasmic domain of Dscam is required for instructing presynaptic terminal growth. 
Overexpression of full-length Dscam under the control of ppk-Gal4 (a, middle) leads to 
exuberant presynaptic terminal overgrowth when compared to control (a, top). However, 
overexpression of DscamΔCyto a, bottom) fails to increase presynaptic terminal growth. Scale 
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bar is 10 μm. (b) Dscam binds Abl via its cytoplasmic domain. S2 cells were co-transfected with 
Abl::Myc along with either Dscam::GFP, DscamΔCyto::GFP, or an empty vector. Dscam::GFP 
was immunoprecipitated with anti-GFP antibody and bound Abl::Myc was examined with anti-
Myc antibody (top). Immunoprecipitated Dscam::GFP and input Dscam::GFP was examined 
with anti-GFP (bottom). (c) Abl colocalizes and redistributes with Dscam but not with 
DscamΔCyto in presynaptic terminals in vivo. When expressed alone, Abl::Myc shows a diffuse 
pattern (bottom). When expressed along with Dscam::GFP (top), Abl::Myc redistributes into 
punctate structures that colocalize with Dscam::GFP. When expressed along with 
DscamΔCyto::GFP (middle), Abl::Myc does not redistribute, displaying a similar pattern to 
when Abl::Myc is expressed alone (bottom). This is quantified using Manders' Correlation 
Coefficient. M1 presents a measure of the fraction of Abl::Myc that overlaps with 
Dscam(ΔCyto)::GFP, while M2 presents a measure of the fraction of Dscam(ΔCyto)::GFP that 
overlaps with Abl::Myc. Both M1 and M2 are significantly increased in Abl-Dscam 





Figure 2.6 DscamΔCyto::GFP is trafficked to presynaptic terminals at a similar level to 
Dscam::GFP. 
Both Dscam::GFP (left) and DscamΔCyto::GFP (right) are trafficked to presynaptic terminals. In 
addition, presynaptic terminal overgrowth is observed 100% of the time when Dscam::GFP is 
overexpressed, while presynaptic terminal overgrowth is never observed when 
DscamΔCyto::GFP is overexpressed. Top image shows merged images mCD8::mRFP (red) and 
either Dscam::GFP or DscamΔCyto::GFP (green). Bottom images show Dscam::GFP or 





Figure 2.7 Dscam activates Abl kinase in culture and in vivo. 
(a) Dscam activates Abl in cultured S2 cells. Abl activation was examined in S2 cell lysates 
transfected with indicated constructs by using anti-phospho-Y412-Abl antibody. The intensity of 
phospho-Abl was quantified, normalized to total Abl::Myc, and presented as bar graph (n = 3) 
(A, right). (b) Schematic of Pickles2.31, an Abl activity reporter that uses phosphorylation of 
CrkL to report Abl kinase activity. Pickles2.31 is composed of a fragment of human CrkL that 
contains an Abl phosphorylation site, Y207, sandwiched between ECFP and Venus. 
Phosphorylation of Pickles2.31 by Abl can be detected with an anti-phospho-Y207-CrkL (p-
CrkL) antibody. (c) Schematic of in vivo assay for detecting Abl activity in C4da presynaptic 
terminals. Pickles2.31 is specifically expressed in C4da neurons. As can be appreciated from the 
larval fillet diagram (left), the cell bodies and dendrites of C4da neurons reside in the larval body 
wall while their presynaptic terminals reside in the CNS. To assay Abl activity only in 
presynaptic terminals, larval CNS are dissected out and solubilized into lysates. Pickles2.31 in 
the presynaptic terminals is then immunoprecipitated with an anti-Venus antibody (left). After 
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running on an SDS-PAGE gel, Pickles2.31 expression level can be assayed using an anti-Venus 
antibody, while the phosphorylation of Y207, a proxy for Abl activity level, can be ascertained 
by western blotting with a p-CrkL antibody. (d) Dscam activates Abl in presynaptic terminals in 
vivo. Overexpression of BCR-Abl leads to a robust increase in p-CrkL staining of Pickles2.31 
when compared to the mCD8-mRFP control. Similarly, overexpression of Dscam leads to 
consistent, though less extreme, increase in p-CrkL when compared to control. In contrast, 
overexpression of DscamΔCyto is indistinguishable from the mCD8-mRFP control. This is a 





Figure 2.8 Phospho-Y412-Abl antibody specifically reports Abl activation. 
S2 cells were transfected with either Abl::Myc or Abl-K417N::Myc. Myc was blotted to report 
total Abl::Myc or Abl-K417N::Myc level (middle), while phosho-Y412-Abl (p-Abl) was blotted 
to report Abl kinase activation (top). While Abl::Myc displays a characteristic two-band pattern 
at the correct molecular weight when blotted for p-Abl, no signal is detected for Abl-K417N. 





Figure 2.9 Pharmacological inhibition of Abl mitigates the neuronal defects caused by 
increased Dscam expression in vivo.  
(a) Nilotinib inhibits Drosophila Abl kinase. S2 cells were transfected with either Myc-vector or 
Abl::Myc, and then treated with either vehicle (DMSO) or 5 μM nilotinib for 6 hr. Total lysates 
were subjected to western blot analysis with phospho-Y412-Abl (p-Abl) (top) and Myc 
antibodies (bottom). (b) Quantification of the presynaptic terminal length of the indicated 
genotypes and drug treatment. Sample number is shown inside each bar. (c–h) Nilotinib 
treatment mitigates presynaptic arbor enlargement caused by Dscam overexpression (OE Dscam, 
d and e) and by dFMRP mutations (dFMRPΔ50M, g and h). Nilotinib treatment alone does not 
affect presynaptic terminal growth (f). The arrowhead in each panel points to the location where 
an axon elaborates the presynaptic terminal arbor. The MARCM technique was used to generate 
and visualize single presynaptic terminals of mutant C4da neurons. Drosophila larvae were 
raised in the presence of either 380 μM nilotinib or vehicle (DMSO) for 4 days before the 




Figure 2.10 Nilotinib and bafatinib do not reduce Dscam transgene expression. 
Example images of C4da presynaptic terminals expressing Dscam::GFP in animals fed either 
vehicle (a and b, top), 380 µM nilotinib (a, bottom), or 125 µM bafetinib (b, bottom) throughout 
larval development. Images of mCD8::mRFP are shown to indicate the neuropil regions used for 
the quantifications (white dotted line). Scale bar is 10 μm. Quantification of the fluorescence of 
the Dscam::GFP transgene in neuropil region is shown on the right. Sample number is shown 





Figure 2.11 Nilotinib treatment does not cause defects in dendritic development or adult 
viability. 
 (a and b) Nilotinib does not affect dendritic development. After egg collection, the animals were 
raised on food containing either vehicle (DMSO) or 380 µM nilotinib for 4 days. C4da dendrites 
were visualized by expressing mCD8::GFP with ppk-Gal4 (a). Total dendritic length was 
measured, quantified, and presented in the bar graph (b). Sample number is shown inside each 
bar. Scale bar is 50 µm. (c and d) Nilotinib does not affect the development of the flies. After 
egg collection, the animals were raised on food containing either vehicle (DMSO) or 380 µM 
nilotinib. Eclosed adults were counted on a daily basis. Total number and cumulative number of 




Figure 2.12 Nilotinib and bafetinib act through Abl inhibition to mitigate Dscam-induced 
presynaptic arbor enlargement in vivo.  
The MARCM technique was used to generate and visualize single presynaptic terminals of 
mutant C4da neurons. Drosophila larvae were raised in the presence of 380 µM nilotinib, 125 
µM bafetinib, or vehicle (DMSO) for 4 days before the analysis. Scale bar is 10 µm. (a–d) 
Nilotinib acts through Abl inhibition to mitigate presynaptic arbor enlargement in Dscam 
overexpressing neurons. Wt (wild-type, FRT2A), OE Dscam (overexpression of Dscam), OE 
Dscam, abl1 (overexpression of Dscam in abl1 homozygous mutations). Note that nilotinib does 
not further decrease the size of presynaptic arbors in abl1 neurons overexpressing Dscam (c and 
d). (e and f) Bafetinib mitigates presynaptic arbor enlargement in Dscam overexpressing 
neurons. (g) Quantification of the presynaptic terminal length of the indicated genotype and drug 





Figure 2.13 Abl phosphorylates a tyrosine residue in the Dscam cytoplasmic domain. 
While co-expression of Dscam and Abl leads to a band that is recognized by a phospho-specific 
antibody and matches the size of Dscam, co-expression of Dscam with all cytoplasmic tyrosines 
mutated to phenylalanine (Dscam-AllF) with Abl does not produce this band. This suggests that 
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 Chapter 3 Dscam and APP-like cooperate to control presynaptic arbor size 
3.1 Abstract  
 Previous studies suggest that Dscam and APP levels are increased in Down syndrome 
and may be increased in Fragile X syndrome. Furthermore, increased levels of Dscam or APP 
promote axon terminal growth in separate systems and require Abl. Despite these similarities, it 
is not clear whether Dscam and APP interact with one another to influence axon development. 
We show here that the Drosophila homolog of APP, Appl, promotes presynaptic arbor growth in 
a system that was previously used to study the role of Dscam in presynaptic arbor size control. 
Furthermore, we show that Dscam and Appl are mutually required and that Appl requires Abl to 
promote presynaptic arbor growth in this system. Finally, we show that simultaneous increases in 
Dscam and Appl expression leads to a synergistic presynaptic arbor phenotype, where 
presynaptic arbor growth is increased beyond that seen when Dscam or Appl are increased 
individually. These results suggest that Dscam and Appl may interact to control Abl activation 
and concurrent increases in Dscam and Appl might contribute to the pathogenesis of disorders 
like Down syndrome and Fragile X syndrome. 
3.2 Introduction 
3.2.1 Potential interactions of Dscam with other molecules 
 Several lines of evidence from our studies and others suggest that other molecules may be 
involved in translating Dscam expression level into presynaptic arbor size. First, I found that 
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overexpression of DsamΔCyto appears to act as a dominant-negative, decreasing levels of Abl 
phosphorylation below wildtype levels. However, the mechanism through which Dscam would 
act as a dominant negative is unclear, suggesting that other molecules may be involved in this 
pathway. Furthermore, Abl is known to promote axon growth in several other systems and to 
interact with cell adhesion molecules other than Dscam, suggesting that several separate or 
intertwined pathways may converge on Abl to control presynaptic arbor size (Leyssen et al., 
2005; Soldano et al., 2013). Two scenarios could be imagined: multiple upstream molecules 
could act separately to control Abl activation, interacting only through their convergent influence 
on Abl, or Dscam could cooperate with another cell adhesion molecule as coreceptors that 
together modulate Abl activity. With these possibilities in mind, I noticed that Amyloid 
Precursor Protein-like (Appl) has previously been shown to require Abl to promote axon and 
presynaptic arbor growth in two different Drosophila systems (Leyssen et al., 2005; Soldano et 
al., 2013). Appl is the Drosophila homolog of Amyloid Precursor Protein (APP), which is known 
to be an important player in the pathogenesis of Alzheimer’s disease. I thus wondered whether 
Dscam might interact with Appl to control Abl activation and this presynaptic arbor growth.  
3.2.2 Down syndrome and Alzheimer’s disease 
 Alzheimer’s disease was first described in 1907 by Dr. Alois Alzheimer, who performed 
an autopsy on a 55-year-old woman who had died from a progressive cognitive and behavioral 
disorder. Alzheimer found two distinctive pathological features in her brain, neurofibrillary 
tangles and neuritic plaques. At the time, he correctly inferred that the observed neurofibrillary 
tangles were abnormal intracellular aggregates and described the neuritic plaques as misshapen 
neuronal processes surrounding “pathological metabolic substance”(Alzheimer et al., 1995). It 
was not until later that the observed neurofibrillary tangles were shown to be composed of hyper-
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phosphorylated tau and the neuritic plaques of a 4.2 kDa peptide, 40 or 42 amino acids in length 
(Glenner and Wong, 1984). Glenner and Wong correctly surmised that this 4.2 kDa peptide was 
likely cleaved from a larger precursor, which was confirmed in 1987 when the amyloid precursor 
protein (APP) was cloned (Kang et al., 1987). The pathological substance observed by 
Alzheimer has subsequently become known as the amyloid-β peptide, or Aβ peptide. 
 In 1968, the link between the amount Aβ deposition and the risk of dementia was 
established (Blessed et al., 1968), and the disorder that Alzheimer had considered to be a “special 
illness” is now recognized as a common dementing disorder, currently afflicting 26 million 
people, with that number expected to quadruple by year 2050 (Brookmeyer et al., 2007). 
Furthermore, Alzheimer’s disease is thought to account for 40-70% of the cognitive variance that 
is seen in the elderly (Dolan et al., 2010). Among people 71 years old and older in the United 
States, 16 percent of women have Alzheimer’s disease and 11 percent of men have Alzheimer’s 
disease (Plassman et al., 2007; Seshadri et al., 1997).  
 The prevalence of Alzheimer’s disease is much higher in Down syndrome patients, with 
an earlier age of onset. Down syndrome patients with complete trisomy of chromosome 21 
universally develop the amyloid plaques and neurofibrillary tangles by the age of 40. Mean age 
of Alzheimer’s diagnosis in people with Down syndrome is 55, and about 95% of Down 
syndrome patients develop dementia by the age of 68 (McCarron et al., 2014). This striking 
phenomenon is thought to arise from the increased copy number of APP, which is located on the 
duplicated chromosome 21. Consistent with this idea, the alteration in APP gene dosage leads to 
an approximately 1.5-fold increase in APP mRNA transcript abundance in Down syndrome 
brains (Oyama et al., 1994). Furthermore, duplication of the APP locus in patients without Down 
syndrome causes autosomal dominant early-onset Alzheimer’s disease, where duplication of a 
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locus including APP and only 4 other genes was sufficient for the development of Alzheimer’s 
disease pathology (Rovelet-Lecrux et al., 2006). Finally, partial trisomy of chromosome 21 distal 
to 21q and therefore excluding APP does not lead to the development of Alzheimer’s disease 
pathology, further supporting the idea that three copies of APP drive the development of early-
onset Alzheimer’s disease in Down syndrome (Prasher et al., 1998). 
3.2.3 Physiological functions of APP 
 APP is part of a small gene family that includes APLP1 and APLP2 in humans, APP-like 
(Appl) in Drosophila and apl-1 in C. elegans. Though APP is evolutionarily conserved from 
worms to humans, the physiological function of APP is still hotly debated. In particular, the 
initial phenotype of APP-deficit mice was rather underwhelming. These mice were viable and 
fertile though they had lighter body mass, age-related weakness in the extremities, and sporadic 
reactive gliosis was observed in the brain (Zheng et al., 1995). Further analysis has since 
revealed subtle defects in exploratory behavior and spatial learning (Tremml et al., 1998). 
However, double mutant of members of the APP gene family produced more compelling 
phenotypes, suggesting that the members of the APP gene family are essential genes with 
overlapping functions. Alone, APLP1-deficient mice have a postnatal growth defect (Heber et 
al., 2000) and APLP2-deficient mice appear completely normal (von Koch et al., 1997). In 
contrast, APP/APLP2 or APLP1/APLP2 double knockouts exhibited early postnatal lethality 
(Heber et al., 2000; von Koch et al., 1997). The final dual gene deficiency, APP/APLP1, was 
viable, fertile and without additional abnormalities as compared the single knockouts (Heber et 
al., 2000). Taken together, these results suggest that the APP gene family is essential for normal 
development and survival. 
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 What is the normal physiological function of APP gene family members? One of the 
earliest APP functions to be discovered was its role in cellular growth, where decreased 
expression of APP slows fibroblast growth (Saitoh et al., 1989). This function was later mapped 
to the pentapeptide (RERMS) domain of APP, which is located near the middle of the 
extracellular domain (Ninomiya et al., 1993). Infusion of either the pentapeptide or secreted APP 
into the brain increased synaptic density and improved memory retention in mice and rats 
(Meziane et al., 1998; Roch et al., 1994). A role for APP in synaptic development is supported 
by the finding that APP/APLP2 double knockout mice have defects in neuromuscular junction 
(NMJ) formation and show aberrant apposition of pre- and post-synaptic proteins. The number of 
synaptic vesicles at each active site was also found to be reduced (Wang et al., 2005). The 
importance of APP for synapse formation is also conserved in Drosophila, where loss of Appl 
causes a decrease in bouton number in the NMJ. Congruently, overexpression of Appl in the 
Drosophila NMJ leads to increased bouton number and alterations in synaptic structure (Torroja 
et al., 1999b). 
 In addition to promoting synapse formation, APP stimulates neurite outgrowth in a 
variety of settings (Hoe et al., 2009; Koo et al., 1993; Qiu et al., 1995; Small et al., 1994; Young-
Pearse et al., 2008). Consistent with a role of APP in normal neuronal development, upregulation 
of APP expression is seen during neuronal maturation of primary hippocampal cultures (Hung et 
al., 1992). This upregulation during development is also seen in studies in Drosophila, where 
Appl is enriched areas of synapse formation and in growing axons (Torroja et al., 1996). 
Relatedly, Appl has been shown to play a role in axonal outgrowth in Drosophila, where 
increased expression of human APP and Drosophila Appl lead to increased arborization of small 
lateral ventral neurons in the adult central nervous system (Leyssen et al., 2005). This 
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conservation of function from mammals to invertebrates also argues for conserved function of 
APP family members in development. Furthermore, previous studies suggest that, like Dscam, 
Appl signals through Abl. In the adult Drosophila small lateral ventral clock neurons (sLNv), 
Abl is required for Appl to promote axonal arborization. In this system, overexpression of human 
APP leads to increased axonal arborization, which can be mitigated by either the removal of a 
single copy of abl or by simultaneous overexpression of a kinase-dead form of Abl (Leyssen et 
al., 2005). In another adult Drosophila cell type, the mushroom bodies, Appl is required for both 
α- and β-axon growth. Simultaneous loss of both copies of Appl and one copy of abl led to a 
more penetrant loss of β-axons, and overexpression of Abl in mushroom bodies lacking Appl 
rescued β-axon growth, suggesting that Abl is downstream of Appl in mushroom body axon 
growth (Soldano et al., 2013). Given that both Dscam and Appl promote neurite growth, it is 
especially intriguing that both of these genes are upregulated in both Down syndrome and 
Fragile X syndrome. 
3.2.4 APP expression is increased in Down syndrome and Fragile X syndrome 
 Analysis of partial trisomy 21 patients suggests that APP is not required for the 
development of intellectual disability in Down syndrome but suggested that its duplication may 
contribute to the intellectual disability phenotype (Korbel et al., 2009). As mentioned earlier, 
increased APP mRNA is found in the brains of Down syndrome patients, where it is suspected to 
contribute to the development of early-onset Alzheimer’s disease (Oyama et al., 1994). In Fragile 
X syndrome, studies in mice show that FMRP binds to and regulates the translation of APP 
(Westmark and Malter, 2007). Importantly, loss of FMRP leads to increased APP expression, 
and levels of soluble Aβ40 and Aβ42 are increased in FMR1 knockout mice (Westmark and 
Malter, 2007). Interestingly, levels of secreted APP are two or more times higher in children with 
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severe autism than in those without autism, and the amount of secreted APP correlated with 
symptom severity, such that children with severe autism had higher levels of secreted APP than 
children with mild autism (Sokol et al., 2006). Taken together, these data suggest that APP is 
likely to be increased in both Down syndrome and Fragile X syndrome, where it may contribute 
to development of intellectual disability in each disorder. 
 In this chapter I show that Appl promotes presynaptic arbor growth in C4da presynaptic 
arbors. Furthermore I show that Dscam and Appl are mutually required to promote presynaptic 
arbor growth and that Appl also requires Abl in C4da neurons. In addition, I present evidence 
that the mechanism through which Appl influences presynaptic arbor growth may not be through 
protein trafficking. In addition, I show that Appl requires the conserved E1 extracellular domain 
to promote presynaptic arbor growth. Finally, I show that Dscam and Appl act synergistically to 
promote presynaptic arbor growth when expression of both proteins is increased, suggesting that 
simultaneously increased Dscam and Appl levels may lead to more severe consequences in 
Down syndrome and Fragile X syndrome than changes in either of these proteins alone. 
3.3 Materials and Methods 
3.3.1 Fly strains  
abl
1
 (Gertler et al., 1989), abl
4
 (Bennett and Hoffmann, 1992), Appl
d 
(Luo et al., 1992), Dscam
18
 
(Wang et al., 2002), Dscam
P1
 (Schmucker et al., 2000), ppk-Gal4 (Kuo et al., 2005), UAS-
Dscam[3.36.25.2]::GFP (Yu et al., 2009), UAS-Appl, UAS-Appl.sd, UAS-Appl.s (Luo et al., 
1992; Torroja et al., 1996), UAS-Appl.sd, UAS-Appl.sd.ΔNPTY, UAS-Appl.sd.ΔCg, UAS-
Appl.sd.ΔE1, Appl.sd.ΔE2 (Torroja et al., 1999b), UAS-APP695-N-myc, and UAS-
APP695.SPA4.CT.T-N-myc (Fossgreen et al., 1998) were used in this study. 
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3.3.2 Labeling presynaptic terminals using MARCM 











, and overexpressing Dscam[3.36.25.2]::GFP or Appl as previously 
described (Kim et al., 2013).  
3.3.3 Immunostaining and imaging  
Immunostaining of third-instar larvae was accomplished as previously described (Ye et al., 
2011). Antibodies used include chicken anti-GFP (Aves, Tigard, Oregon) and rabbit anti-RFP 
(Rockland, Limerick, Pennsylvania). Samples were dehydrated and mounted with DPX 
mounting media (Electron Microscopy Sciences, Hatfield, Pennsylvania). Confocal imaging was 
completed with a Leica SP5 confocal system equipped with a resonant scanner and 63× oil-
immersion lens (NA = 1.40). Images were collected and quantified as previously described (Kim 
et al., 2013).  
3.3.4 Statistical analysis 
Two-way student’s t- test was used for statistical analysis. *: p < 0.05; **: p < 0.01; ***: p < 
0.001; ****: p < 0.0001; ns: not significant. 
3.4 Results 
3.4.1 Appl promotes presynaptic arbor growth in C4da neurons 
 In order to ask whether overexpression of Appl promotes presynaptic arbor growth in 
C4da neurons, I overexpressed Appl under the control of the UAS promoter in all C4da neurons 
using ppk-Gal4. Consistent with previous reports, increased expression of Appl led to a robust 
increase in presynaptic arbor growth (Figure 3.5 b).  
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3.4.2 Dscam and Appl are mutually required to promote presynaptic arbor growth 
 Since overexpression of Appl and overexpression of Dscam produce similar phenotypes, 
I next asked whether Dscam requires Appl to instruct presynaptic arbor growth. Consistent with 
previous experiments, overexpression of Dscam in single C4da neurons using MARCM led to a 
significant increase in presynaptic arbor length (Figure 3.1 b,e). Furthermore, Appl
d
 mutant 
clones alone were significantly shorter than wildtype (Figure 3.1 c,e), suggesting that Appl 
instructs presynaptic arbor size in C4da neurons. Appl
d
 mutant clones that overexpressed Dscam, 
however, did not differ significantly in length from Appl
d
 clones, and were significantly shorter 
than clones that overexpressed Appl in a wildtype background (Figure 3.1 d,e). These results 
suggest that Appl instructs presynaptic arbor growth in C4da neurons and that Dscam requires 
Appl to instruct presynaptic arbor growth.  
 Although these results indicate that Dscam requires Appl, they do not distinguish 
between two possible scenarios: that Appl is downstream of Dscam, and that Dscam and Appl 
are mutually required. To assess the relationship of Appl to Dscam in presynaptic arbor size 
control, I next asked whether Appl requires Dscam to instruct presynaptic arbor growth. 
Overexpression of Appl in single clones led to an extremely robust increase in presynaptic arbor 
length (224%) as compared to wildtype clones (Figure 3.2 a,b,g). Consistent with previous 
reports, Dscam
18
 mutant clones had severely truncated presynaptic arbors, and were highly 
significantly shorter than wildtype clones (Figure 3.2 c,g). Dscam
18
 mutant clones that 
overexpressed Appl were significantly shorter than wildtype clones overexpressing Appl, but 
remained slightly but significantly longer than Dscam
18
 mutant clones that did not overexpress 
Appl (Figure 3.2 d,g). To confirm this result, I repeated these experiments using a different 
mutant allele of Dscam, Dscam
P1







clones that overexpressed Appl were significantly shorter than wildtype clones that 
overexpressed Appl, but remained slightly but significantly longer than Dscam
P1
 clones that did 
not overexpress Appl (Figure 3.2 e,f,g). These results suggest that Appl also requires Dscam to 
instruct presynaptic arbor growth, and therefore Appl and Dscam are mutually required to 
control presynaptic arbor size. Furthermore, these results suggest that Appl also exerts a portion 
of its effects on presynaptic arbor size through another, yet unidentified, pathway that is 
independent of Dscam. 
3.4.3 Appl requires Abl to promote presynaptic terminal growth 
 Next, since Appl requires Dscam to instruct presynaptic arbor size, I asked whether Abl 
is also required by Appl in C4da neurons. To do this, I overexpressed Appl in either wildtype or 
abl
1
 single C4da neurons using MARCM. Compared to single C4da neurons overexpressing 
Appl, which had significantly and extremely robustly increased presynaptic arbor lengths as 
compared to wildtype (715%) (Figure 3.3 b, g), abl
1
 mutant clones that overexpressed Appl were 
significantly shorter (Figure 3.3 d,g). Importantly, abl
1
 mutant clones that overexpressed Appl 
were significantly longer than abl
1
 clones that did not overexpress Appl (Figure 3.3 c,d,g). This 
result was confirmed using an independent mutant allele of abl, abl
4
. Taken together, these 
results suggest that Appl requires Abl to instruct presynaptic arbor size, but that Appl also 
signals through another, yet unidentified, pathway to affect presynaptic arbor size. 
3.4.4 Constitutively secreted Appl is not sufficient to promote presynaptic arbor growth 
  I next asked which portions of the Appl molecule are required to promote presynaptic 
terminal growth. To do this, I overexpressed a previously generated collection of mutated UAS-
Appl constructs in C4da neurons using ppk-Gal4 (Torroja et al., 1999b). Appl is known to be 
proteolytically processed by cleavage at identified sites in the extracellular domain, which leads 
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to the release of soluble forms of Appl (Fossgreen et al., 1998; Luo et al., 1992; Torroja et al., 
1996). I thus asked whether a constitutively secreted form of Appl, Appl.s or secretion deficient 
form of Appl, Appl.sd could promote presynaptic terminal growth. Appl.s is a form of Appl that 
lacks the cytoplasmic and transmembrane domains and is thus constitutively secreted (Figure 
3.4). Overexpression of Appl.s did not lead to an appreciable change in presynaptic arbor size, 
and if anything may decrease the number of connectives, though further analysis with MARCM 
would be necessary to confirm this phenotype (Figure 3.5 c). Appl.sd is a secretion-deficient 
form of Appl that has a 34 amino-acid in-frame deletion (amino acids 758-791) as well as two 
point mutations (Arg795Arg796 – Leu795Ser796). The point mutations alone are not sufficient to 
prevent Appl secretion, suggesting that the 34 amino acid deletion contains the sites necessary 
for Appl processing. In contrast to Appl.s, Appl.sd was able to promote presynaptic arbor 
growth, though not to the same extent as wildtype Appl (Figure 3.5 d). These data suggests that 
secreted Appl does not promote presynaptic arbor growth, but that the region deleted in Appl.sd 
or the associated point mutations may be necessary for one, but not all, of the signaling pathways 
through which Appl impacts presynaptic arbor growth.  
3.4.5 Appl requires the E1 extracellular domain to promote presynaptic arbor growth 
 I next tested which domains of Appl were required to promote presynaptic arbor growth 
using a series of mutants, all of which had the .sd mutation to examine the secretion-independent 
roles of Appl. I focused on conserved domains that were identified by comparing APP and Appl 
(Rosen et al., 1989). These include a conserved internalization sequence in the cytoplasmic 
domain (GYENPTY) (Appl.sdΔNPTY) and two extracellular domains with high sequence 
homology with APP, E1 (Appl.sdΔE1) and E2 (Appl.sdΔE2). I further tested the conserved GO 
binding site (Appl.sdΔCg), which has been demonstrated to play a role in the signaling of both 
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APP and Appl (Nishimoto et al., 1993; Okamoto et al., 1995). The constructs have the following 
deletions: Appl.sdΔNPTY which lacks the GYENPTY internalization sequence and surrounding 
amino acids (872-883), Appl.sdΔE1 deletes the distal half of the E1 as well as a number of 
amino acids located on the c-terminal side of E1 (85-321 aa), Appl.sdΔE2 deletes 75% of the 
distal region of E2 as well as some amino acids c-terminal to it (449-740 aa), and Appl.sdΔCg, 
which deletes the putative GO-protein binding site (845-855 aa) (Figure 3.4). These constructs 
have previously been demonstrated to be expressed and at comparable levels to one another 
(Torroja et al., 1999b). I overexpressed these constructs in all C4da neurons under the control of 
ppk-Gal4. 
  Overexpression of Appl.sdΔNPTY did not lead to a decrease in presynaptic terminal 
growth as compared to Appl.sd but did lead to an additional neuropil phenotype, suggesting that 
the internalization sequence may be important for proper synapse formation in the connectives 
(Figure 3.5 e). Overexpression of Appl.sdΔE1, however, failed to promote presynaptic arbor 
growth (Figure 3.5 g), suggesting that part of the N-terminal half of the extracellular domain is 
required for Appl to promote presynaptic arbor growth through both Dscam/Abl and through its 
other signaling pathway(s). In contrast to Appl.sdΔE1, Appl.sdΔE2 did not compromise Appl’s 
action on presynaptic arbor growth and, surprisingly, overexpression of Appl.sdΔE2 was 
indistinguishable from that of wildtype Appl (Figure 3.5 h). This result is unexpected because 
deletion of the E2 domain appears to rescue the defects caused by the .sd mutation. Finally, 
overexpression of Appl.sdΔCg resulted in a phenotype that was indistinguishable from 
overexpression of Appl.sd (Figure 3.5 f). This result suggests that either the GO-protein binding 
site is not required for Appl to promote presynaptic arbor growth or that the GO-protein binding 
site is involved in the same pathway that is impacted by the .sd deletion. Taken together these 
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results suggest that the E1 region in particular is important for Appl to promote presynaptic arbor 
growth and provides further evidence that Appl signals through two or more distinct pathways to 
regulate presynaptic arbor size, one of which requires Dscam/Abl. 
3.4.6 Appl is not required for Dscam/Abl colocalization in C4da presynaptic arbors 
 Since both Appl and Dscam require Abl, and loss of Appl prevents Dscam from 
promoting presynaptic arbor growth, we next asked whether Dscam requires Appl to associate 
with Abl. Our previous work has shown that Dscam::GFP and Abl::myc colocalize in 
presynaptic arbors in vivo and that this colocalization is dependent on the Dscam cytoplasmic 
domain. We thus used the same assay to ask whether loss of Appl would decrease colocalization 
of Dscam::GFP and Abl::myc in presynaptic arbors. To do this, we overexpressed Dscam::GFP 
and Abl::myc either in a wildtype or an Appl
d
 mutant background and assayed colocalization. As 
in the wildtype background, co-expressed Dscam::GFP and Abl::myc exhibited nearly complete 
colocalization in the Appl
d
 mutant (Figure 3.6, middle and bottom). Strikingly, however, we 
noticed a conspicuous change in Dscam::GFP localization within presynaptic arbors, such that 
Dscam::GFP became clumped into large puncta (Figure 3.6, bottom). As might be expected, 
Abl::myc was redistributed to match the location of Dscam::GFP puncta. These results suggest 
that Appl is not required for Dscam-Abl binding, but that Appl may be important for Dscam 
localization in presynaptic arbors. 
3.4.7 Loss of Appl does not block presynaptic arbor growth by decreasing Dscam 
trafficking to the presynaptic arbors 
 Previous studies have suggested that Appl is involved in axonal transport and that Appl 
functions as a vesicular receptor for kinesin-1 (Gunawardena and Goldstein, 2001; Torroja et al., 
1999a). Importantly, these studies showed that loss of Appl led to axon blockages or “organelle 
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jams” which led to punctate aggregations of the observed proteins, including synaptotagmin and 
cysteine string protein. Thus, to test whether Appl is required to transport Dscam to the 
presynaptic arbor, we first asked whether loss of Appl altered Dscam expression level and 
distribution in matched samples that were stained and imaged simultaneously to allow for direct 
comparison of Dscam expression level. I hypothesized that if Appl is required to transport 
Dscam to presynaptic arbors that Dscam-GFP should form punctate axon blockages in axon 
shafts and decreased Dscam-GFP should be observed in the presynaptic arbors in Appl mutants. 
While Dscam-GFP was present in large bright puncta in the axon shafts and presynaptic 
terminals of Appl mutants, Dscam-GFP intensity was far brighter in the presynaptic arbors as 
compared to controls (Figure 3.7, right). This result suggests that loss of Appl does not impair 
Dscam trafficking to presynaptic arbors, but rather may enhance it. In addition, it suggests that 
the reduction of presynaptic arbor growth in Appl mutants overexpressing Dscam is unlikely to 
stem from reduced transport of Dscam to presynaptic arbors. 
 Previous studies of Appl’s role in trafficking also demonstrated that both overexpression 
of and loss of Appl led to the same axon blockage phenotype, since overexpression of Appl 
binds up the pool of kinesin-1, preventing kinesin-1 from interacting with other trafficking 
pathways for which it is required. Importantly, these studies predict that Appl loss-of-function 
and Appl gain-of-function should result in the same phenotype in systems that rely on Appl’s 
role as a vesicular receptor for kinesin-1 (Gunawardena and Goldstein, 2001). Our system does 
not seem to fit this model, as gain and loss of Appl function lead to changes in opposite 
directions. In particular, loss of Appl leads to significantly decreased presynaptic arbor length in 
single C4da neurons while overexpression of Appl in single C4da neurons leads to extremely 
significantly increased presynaptic arbor length (Figures 3.1 c,e, Figure 3.2 b,g and Figure 3.3 
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b,g). Taken together, these data suggests that Appl may not be required for Dscam trafficking in 
our system and may instead act through a yet undiscovered mechanism. 
 Finally, previous studies found that while overexpression of wildtype Appl produced 
axon jams of synaptotagmin and cysteine string protein, overexpression of Appl lacking the 
cytoplasmic domain, which contains a conserved region that contains a kinesin-1 binding site, 
failed to produce these jams (Gunawardena and Goldstein, 2001). Furthermore, Appl genetically 
interacts with kinesin-1 to facilitate axon transport. I reasoned that if Appl’s interaction with 
kinesin-1 is required in our system, Appl lacking its cytoplasmic domain should be unable to 
promote presynaptic arbor growth. Overexpression of an Appl construct that lacks the kinesin-1 
binding domain should be unable to promote presynaptic arbor growth. Although the collection 
of mutant Appl constructs we tested did not include a mutant which covered the kinesin-1 
binding domain, we were able to access a human APP construct lacking the entire cytoplasmic 
domain. To assess whether the human APP cytoplasmic domain is required for APP to promote 
presynaptic arbor growth, we first asked whether wildtype human APP could promote 
presynaptic arbor growth. Consistent with previous reports suggesting that Appl and APP are 
highly functionally homologous (Luo et al., 1992), overexpression of APP695 also led to 
increased presynaptic arbor growth (Figure 3.8, b). This result suggests that the functional 
domains required for Appl’s effect on presynaptic arbor growth are conserved in human APP. 
We next asked whether loss of the cytoplasmic domain, which includes the kinesin-1 binding 
domain, abolished the increase in presynaptic arbor growth seen when APP was overexpressed 
(Figure 3.8, a). In opposition to the hypothesis that APP exerts its function through influencing 
Dscam trafficking, loss of the kinesin-1 binding domain did not impact Appl’s ability to promote 
presynaptic arbor growth. In fact, the phenotype seen in C4da neurons overexpressing APPΔCT 
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was indistinguishable from that in C4da neurons overexpressing wildtype APP (Figure 3.8, b). 
Both APP and APPΔCT were expressed in presynaptic arbors as seen by the localization of myc 
(Figure 3.8, b, right). This result further suggests that Appl may not promote presynaptic arbor 
growth by increasing Dscam trafficking to the presynaptic arbors.  
3.4.8 Simultaneously increased Dscam and Appl have a synergistic effect on presynaptic 
arbor growth 
 Finally, since APP and Dscam are predicted to have simultaneously increased expression 
in Down syndrome and Fragile X syndrome, I asked how simultaneous overexpression of Appl 
and Dscam would impact presynaptic arbor growth. To do this, I overexpressed Appl and 
Dscam::GFP together in C4da neurons. I found that overexpression of Appl and Dscam led to an 
arrestingly synergistic phenotype, which promoted presynaptic arbor growth so strongly that 
axon arbors left the confined of the C4da axon ladder and grew in all directions (Figure 3.9). 
These Appl and Dscam overexpressing C4da axon ladders were easily distinguishable from those 
overexpressing either Appl or Dscam alone (Figure 3.9). This result is significant because it 
suggests that concurrent increases in APP and Dscam could lead to even more significant 
changes in axon development than increased levels of either APP or Dscam alone.  
3.5 Discussion 
 In this study, we showed that Dscam and Appl are mutually required to promote 
presynaptic arbor growth and that Appl, like Dscam, requires Abl. We further showed that 
simultaneous overexpression of Appl and Dscam has a synergistic phenotype, suggesting that 
coincident increases of APP and Dscam, as is seen in Down syndrome and Fragile X syndrome, 
may lead more severe changes in development than increased Dscam or APP alone. 
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 One interesting prediction gleaned from our Dscam-Appl epistasis experiments is that 
Appl requires Dscam and Abl but may also act through another, yet unidentified signaling 
pathway. This prediction is supported by our analysis of the Appl.sd mutant construct, 
overexpression of which led to an intermediate phenotype. This suggests that the region deleted 
in .sd is required for one pathway, but not all, through which Appl promotes presynaptic arbor 
growth. We hypothesize that, in addition to Abl, Appl may also signal through the GO-protein, 
which has previously been implicated in promoting synaptic bouton formation in the Drosophila 
NMJ (Torroja et al., 1999b). The observation that deletion of the GO-binding site in the Appl.sd 
construct does not lead to further reductions in presynaptic arbor growth does not rule out the 
participation of GO. If the mutation in .sd is also required for GO function in our system, further 
deletion of the GO-binding site would not lead to further changes in Appl’s ability to promote 
presynaptic arbor growth. However, further experiments are required to determine whether Appl 
also signals through GO-protein in C4da presynaptic arbor size control. 
 Another intriguing question raised by this study relates to the somewhat contradictory 
phenotypes seen when overexpressing Appl versus APP deletion constructs. Overexpression of 
the Appl.sd deletion constructs shows that deletion of the conserved GYENPTY internalization 
(Appl.sdΔNPTY) sequence on the Appl cytoplasmic domain leads to a neuropil phenotype in 
C4da neurons. In contrast, overexpression of APPΔCT, which also lacks the internalization 
sequence, was indistinguishable overexpression of APP in C4da neurons. This discrepancy 
suggests that although APP and Appl seem to share a domain that is capable of promoting 
presynaptic arborization, not all functions or regions are conserved between APP and Appl. 
Thus, future studies that utilize APP and not Appl might produce results that are more readily 
translatable into mammalian systems. 
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 An open question that is not fully addressed by these experiments is the mechanism of 
the interaction between Appl, Dscam, and Abl. Since loss of Appl increases Dscam levels in 
presynaptic arbors and overexpression of an APP construct that lacks the kinesin-1 binding 
domain fully retains its ability to promote presynaptic arbor growth, suggesting that kinesin-1 
mediated transport is not required, it is unlikely that Appl is acting to transport Dscam to 
presynaptic arbors. However, the bright large puncta of Dscam-GFP that are observed in Appl 
mutants may suggest that Appl is important for Dscam turnover or degradation in presynaptic 
arbors. This possibility remains to be tested but is not mutually exclusive of other hypotheses. 
 If Appl does not exert its functions by altering Dscam trafficking to presynaptic arbors, 
an alternative hypothesis is that Appl and Dscam act as co-receptors. Experiments presented here 
suggest that Appl may not facilitate Dscam-Abl binding, as loss of Appl does not disrupt in vivo 
colocalization of Dscam and Abl. However, the corresponding hypothesis, that Dscam mediates 
Appl’s interaction with Abl, remains untested. To test this hypothesis, Appl and Abl co-
immunoprecipitation could be assessed with and without expression of Dscam. If Dscam is 
required to link Appl to Abl, expression of Dscam should increase the amount of Abl that co-
immunoprecipitates with Appl. Furthermore, if Dscam and Appl act as co-receptors, co-
expression of Dscam and Appl should lead to increased activation of Abl when compared to 
either Dscam or Appl alone. This experiment could be performed by expressing Abl-myc with 
either Dscam alone, Appl alone, or Dscam and Appl together in Drosophila S2 cells and 
assessing Abl activation using the phospho-Abl antibody employed in our Dscam-Abl study. If 
Dscam and Appl act as co-receptors, co-expression should lead to increased Abl activation over 
either Dscam or Appl alone. This experiment may be complicated by the endogenous expression 
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of Dscam or Appl in S2 cells, in which case RNAi could be employed to knock down either 
Dscam or Appl expression. 
 Interestingly, the only domain of Appl that appears to be absolutely required to promote 
presynaptic growth is the E1 extracellular domain. This domain has previously been shown to be 
important for activation of GO-protein (Okamoto et al., 1995) and for APP dimerization (Dahms 
et al., 2010). However, the deletion construct that I tested covered more than just the E1 domain, 
raising the possibility that the region found to be required for Appl to promote presynaptic 
terminal growth has additional functions. In particular, if the experiments described above 
indicate that Dscam and Appl are co-receptors, it might be hypothesized that Appl binds to 
Dscam through the large region deleted in Appl.sdΔE1.  
 Finally, the results presented here suggest that simultaneous overexpression of APP and 
Dscam, as is seen in Down syndrome and likely also in Fragile X syndrome, leads to a 
synergistic phenotype. Thus, the increased expression of two components of the same pathway 
may lead to more severe defects than two components that perform different cellular functions. 
Furthermore, this study provides a possible explanation for two observations in human patients. 
These include that duplication of the APP locus leads to the development of early-onset 
Alzheimer’s disease but not intellectual disability (Rovelet-Lecrux et al., 2006), and the 
identification of APP as a possible contributing factor that was not absolutely required for the 
intellectual disability phenotype in Down syndrome (Korbel et al., 2009). Korbel et al (2009) 
identified several partial chromosome 21 trisomy patients with borderline normal intellectual 
functioning that had three total copies of APP, suggesting that APP may contribute but that three 
copies of APP is not sufficient for the development of intellectual disability. However, they also 
noted two patients with four total copies of APP that had more pronounced intellectual disability, 
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indicating that the contribution of APP may scale with dosage. Thus, the presence of an extra 
copy of APP in an otherwise normal individual may lead to subtle defects that do not 
significantly impact intelligence. However, increased copy number of both Dscam and APP may 
have a synergistic phenotype that noticeably impacts IQ. Finally, the partial dependence of Appl 
on Abl suggests that a similar therapeutic approach could be used to mitigate the consequences 
of increased APP expression and increased Dscam expression for presynaptic arbor size. 
However, whether administration of tyrosine kinase inhibitors rescues presynaptic arbor growth 





Figure 3.1 Dscam requires Appl to promote presynaptic arbor growth. 
 (a-d) Appl is requires in c4da neurons to instruct presynaptic arbor growth. The arrowhead 
shown in each panel points to the location where the axon elaborates the presynaptic arbor. 
While overexpression of Dscam::GFP (b) in single C4da presynaptic terminals leads to increased 
length when compared to control (a), overexpression of Dscam in App
d
 mutant neurons (d) leads 
to presynaptic terminal lengths that are not significantly different in length from Appl
d
 mutant 
neurons (c). However, Appl
d
 mutant neurons are significantly shorter than control neurons, 
suggesting that Appl is required to instruct presynaptic arbor growth. These effects are quantified 





Figure 3.2 Appl requires Dscam to promote presynaptic arbor growth.  
Like Dscam, overexpression of Appl in single C4da neurons leads to a significant increase in 
presynaptic arbor size (b) when compared to control clones (a). As previously reported, Dscam
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mutant neurons (c) have significantly shorter presynaptic arbors than control neurons (a). 
However, overexpression of Appl in Dscam
18
 (d) leads to presynaptic arbors than are 
significantly shorter than those that overexpress Appl in a wildtype background (b) but 
significantly longer than Dscam
18
 mutant neurons that do not have increased Appl . This effect 
was verified with an independent mutant allelle of Dscam, Dscam
P1
 (f and g) and is quantified in 





Figure 3.3 Appl requires Abl to promote presynaptic arbor growth. 
Overexpression of another Appl construct in single C4da neurons (b) leads to very significantly 
increased presynaptic arbor lengths as compared to controls (a). As previously demonstrated, 
abl
1
 mutant C4da neurons have subtly but significantly shorter presynaptic arbors (c). 
Furthermore, overexpression of Appl in abl
1
 neurons leads to significantly shorter presynaptic 
arbors (d) when compared to overexpression of Appl in a wildtype background (b) , but 
significantly longer presynaptic arbor lengths than abl
1
 mutant neurons (c). This result was 
confirmed using an independent mutant allelle of abl, abl
4 
(e and f) and is quantified in (g). Scale 




Figure 3.4 Appl deletion constructs used in this study. 
Wildtype Appl contains two conserved cytoplasmic regions, E1 and E1, a cleavage site (c), a 
transmembrane domain (Tm), a conserved GO-protein binding site (Cg), and a conserved 
internalization sequence (NPTY). Appl.s is a constitutively secreted form of Appl that lacks the 
transmembrane and cytoplasmic regions of Appl, while Appl.sd is a secretion deficient form of 
Appl that contains a short deletion that overs the cleavage site. Appl.sdΔNPTY lacks the 
GYENPTY internalization sequence and surrounding amino acids (872-883), Appl.sdΔE1 
deletes the distal half of the E1 as well as a number of amino acids located on the c-terminal side 
of E1 (85-321 aa), Appl.sdΔE2 deletes 75% of the distal region of E2 as well as some amino 





Figure 3.5 Analysis of Appl deletion constructs in presynaptic terminal growth.  
In contrast to wildtype C4da axon ladders (a), C4da neurons that express wildtype Appl show 
exuberant presynaptic arbor growth (b). Conversely, overexpression of a consistutively secreted 
form of Appl (c) is indistinguishable from wildtype. As compared to C4da neurons that express 
Appl, C4da neurons that overexpress a secretion deficient form of Appl show an intermediate 
phenotype (d), with more presynaptic arbor growth than wildtype C4da neurons, but less growth 
than C4da neurons overexpressing wildtype Appl. When the evolutionarily conserved NPTY 
internalization site is further deleted from Appl.sd, an additional phenotype emerges. C4da 
neurons overexpressing Appl.sdΔNPTY have extremely convoluted and abundant processes in 
the neuropil region (e), suggesting that loss of the internalization sequence may hamper synapse 
formation. In contrast, when the conserved GO-protein binding site is further deleted from the 
Appl.sd cytoplasmic domain (f), the phenotype is identical to Appl.sd. Appl.sd constructs with 
further deletions in two conserved extracellular regions have drastically different phenotypes 
form one another. Deletion of the E1 domain in Appl.sd completely abolishes Appl.sd’s 
promotion of presynaptic arbor growth (g), while deletion of the E2 domain rescues it, such that 
C4da neurons that overexpress Appl.sdΔE2 (h) are indistinguishable from those that overexpress 





Figure 3.6 Appl is not required for Dscam and Abl colocalization in C4da presynaptic 
arbors in vivo.  
Expression of Abl-myc in C4da presynaptic arbors leads to a uniform distribution of Abl-myc 
(red) throughout the presynaptic arbors (top row). Coexpression of Dscam-GFP (green) and Abl-
myc leads to a redistribution of Abl-myc, such that Abl-myc becomes punctate and overlaps 
extensively with Dscam-GFP (middle row). Coexpression of Dscam-GFP and Abl-myc in an 
Appl
d
 mutant background leads to striking redistribution of Dscam-GFP and Abl-myc is also 
further redistributed, maintaining extensive overlap with the Dscam-GFP signal such that their 
patterns in the presynaptic arbors are nearly identical. These results suggest that Appl is not 





Figure 3.7 Loss of Appl leads to redistribution of Dscam-GFP in C4da presynaptic arbors. 
Overexpression of Dscam-GFP in C4da presynaptic arbors leads accumulation of small, dim 
Dscam-GFP (green) puncta throughout the presynaptic arbors, with slightly increased signal in 
the neuropil regions (middle row). In matched samples that were stained and mounted together 
as well as imaged simultaneously using identical imaging parameters, overexpression of Dscam-
GFP in Appl
d
 mutant C4da presynaptic arbors (bottom row) led to redistribution of Dscam-GFP 
into extremely bright, large puncta. Dscam-GFP also formed long intense aggregations in the 
C4da axons as they entered the C4da presynaptic ladder region. Reduction in presynaptic arbor 
growth is also visible in C4da neurons overexpressing Dscam-GFP in an Appl
d
 mutant 
background using a membrane morphology marker, mcD8-RFP (red, center, bottom row) as 





Figure 3.8 Overexpression of human APP695 promotes presynaptic arbor growth and does 
not require the cytoplasmic domain.  
(a) Schematic showing APP-N-myc, which is full-length human APP695 with an N-terminal 
myc tag, and APPΔCT-N-myc, which is constructed as APP-N-myc but lacks the cytoplasmic 
domain. (b) Like Drosophila Appl, overexpression of human APP-N-myc also promotes 
presynaptic arbor growth (top row, left). Myc staining shows that APP-N-myc assumes a 
punctate pattern in the C4da presynaptic arbor ladder (top row, right). An APP construct that 
lacks a region of the cytoplasmic domain that includes the NPTY internalization sequence and 
the conserved kinesin-1 binding domain is expressed in C4da presynaptic arbors and retains its 





Figure 3.9 Coexpression of Appl and Dscam has a synergistic effect on C4da presynaptic 
arbor growth.  
Overexpression of either Dscam (b) or Appl (c) alone leads to increased presynaptic arbor 
growth as compared to wildtype C4da neurons (a). However, both lead to presynaptic terminals 
that, while increased in size, generally remain within the confines of the C4da axon ladder 
(dashed red lines). In contrast, simultaneous overexpression of Dscam and Appl leads to wildly 
overgrowth presynaptic arbors that stay wildtype from the usual location of the C4da presynaptic 




3.6 Description of manuscript and authors’ contributions 
 The experiments described in Chapter 3 of this dissertation have not yet been published at 
the submission of this dissertation. A manuscript is in preparation. 
 The writing, experiments, and figures in Chapter 3 of this dissertation were prepared and 





 The results presented in this dissertation represent the first inroads into understanding the 
signaling mechanisms of Dscam in processes that are controlled by Dscam expression level. In 
particular, we show that Dscam requires Abl to promote presynaptic terminal growth and that 
Dscam-Abl binding and activation is mediated through the Dscam cytoplasmic domain both in 
culture and in vivo. Furthermore, we show that Dscam and Appl are mutually required, and that 
simultaneous upregulation of Dscam and Appl leads to a synergistic phenotype. This represents 
the first evidence that Dscam and Appl genetically interact and suggests that Dscam and Appl 
may act synergistically in the pathogenesis of Down syndrome and Fragile X syndrome. Here we 
discuss the pitfalls and limitations, possible future studies, and the potential of tyrosine kinase 
inhibitors as therapeutics for Down syndrome and Fragile X syndrome.  
4.1 Pitfalls and limitations 
4.1.1  Maternal contribution and mitotic perdurance of gene products in mutant 
analysis of gene functions. 
   
 Although extremely useful and powerful, the use of mutant analysis for studies of gene 
function during development is subject to two important limitations, maternal contribution and 
perdurance. During Drosophila oogenesis, the mother packs the oocyte with the RNAs and 
proteins that will be required for embryonic development prior to the zygotic transition, when the 
zygotic genome will be activated and the degradation of maternal products will commence. This 
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is known as maternal contribution. Thus, even an embryo that is homozygous mutant for a 
certain gene may contain protein and mRNA from that gene which has been contributed by the 
mother. Thus, an embryo can only be assumed to completely lack a protein of interested if the 
mother, too, is homozygous mutant for the relevant gene. Thus, homozygous mutant cells in 
some mutant embryos or larvae may still contain maternally contributed RNA and protein, which 
may, in turn, mask the phenotype caused by loss of that gene. We expect this to be the case of 
Abl, as discussed in Section 2.5. Furthermore, protein and RNA from a gene of interest may still 
be detected in a homozygous mutant neuron generated using MARCM even if that gene is not 
subject to maternal contribution. This can occur when gene products generated by the zygotic 
genome prior to the recombination event persist in the labeled cell. This is phenomenon is known 
as perdurance. 
 Although maternal contribution and perdurance are important to keep in mind when 
interpreting the results of mutant analysis, they rarely render results uninterpretable. In cases 
where maternal contribution in particular obscures the function of a gene in early development, 
the generation of maternal clones can reveal the mutant phenotypes that were masked. 
4.1.2 Co-immunoprecipitation and colocalization analysis 
 The two techniques we used to show that Dscam and Abl interact with one another, co-
immunoprecipitation and colocalization analysis, are limited in that they cannot tell us whether 
Dscam and Abl interact directly with one another. Although it appears that Dscam and Abl may 
at least interact within a common protein complex and that this interaction requires the Dscam 
cytoplasmic domain, it may be that another, yet unknown, adaptor protein or proteins acts as an 
intermediary between Dscam and Abl. The question of whether Dscam and Abl bind directly to 
one another thus remains open, but could be addressed using in vitro binding assays. 
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Colocalization analysis, as a technique, is further limited by the possibility that two proteins may 
appear to colocalize if they are located within the same cellular compartment, even if they do not 
interact. We believe that the results presented here (see Figure 2.5) are informative due to the 
fact that loss of the Dscam cytoplasmic domain abolishes Dscam-Abl colocalization. However, 
this particular technique should be used with caution and in conjunction with other, 
complementary assays. 
4.1.3 Western blotting using S2 cells  
 All of the western blots presented in this dissertation, with the exception of that in Figure 
2.7d, were performed in S2 cells using overexpression of tagged proteins. Thus, when 
interpreting these results, it is important to keep in mind that S2 cells are not neurons. S2 cells 
were derived from primary culture of late stage 20- to 24-hour Drosophila embryos and present a 
macrophage-like lineage (Schneider, 1972). Therefore, experiments done in S2 cells may not 
reflect the environment that would be seen in neurons or in their presynaptic arbors. However, 
our in vivo results corroborate each of the conclusions that were derived from S2 cell 
experiments, suggesting that S2 cells may serve as a useful initial system in which to test 
molecular hypotheses before commencing in vivo investigations. 
 Another caveat to our S2 cells experiments and some of our in vivo experiments is that 
they were performed using overexpression of tagged Drosophila proteins. Although it would be 
ideal to use endogenous proteins, the availability of antibodies that have been raised to recognize 
Drosophila proteins is limited. Furthermore, endogenous proteins may not be expressed at high 
enough levels to be detected using our methods. A risk of using overexpression is the possibility 
of detecting artificial interactions between proteins that result from the high level of expression 
in the system. We believe that this is not the case in our experiments, however, owing to the fact 
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that Dscam and Abl appear to genetically interact in in vivo assays that do not rely on transgene 
overexpression (see Figure 2.1 l, m, n, and p). This cannot be said of the genetic interactions we 
show between Appl and Dscam, however. Future studies should seek to confirm genetic 
interactions between Appl and Dscam without the use of transgenes. However, even if such an 
interaction is not found, these studies are still useful to understand the function of Dscam and 
Appl in situations where their expression levels are increased, as in Down syndrome or Fragile X 
syndrome. To reduce expression to levels that might be seen in human patients with these 
disorders, future studies might use BAC transgenics to increase Dscam or Appl copy number or 
focus on dFMRP mutants. 
4.2 Future work 
 With Dscam, Appl, and Abl as a starting point, future work should focus on expanding 
our understanding of Dscam and Appl signaling. As demonstrated here using Abl, each newly 
identified pathway member represents a novel potential therapeutic target. Two unresolved 
questions in the work presented here are: what is the mechanism by which Dscam and Appl 
interaction and which molecules link Abl to the cytoskeleton after activation by Dscam. A 
number of experiments laid out earlier have the potential to answer the first question by 
differentiating between the hypotheses that Appl controls Dscam trafficking and that Appl and 
Dscam act as co-receptors. The second question may be addressed by first investigating the roles 
of molecules that have previously been shown to interact with Abl, including Enabled (Comer et 
al., 1998), Trio (Hill et al., 1995), and Rac1 (Singh et al., 2010). Further interactors with Dscam 
and Appl may also be identified by using a candidate approach to further illuminate the roles of 
molecules that have previously been implicated in Appl’s signaling in mushroom body neurons 
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and motor neurons. These include Frizzled, Flamingo, Van Gogh, Disheveled (Soldano et al., 
2013), and GO-protein (Torroja et al., 1999b). 
 We describe here a proof-of-concept experiment that presents tyrosine kinase inhibitors 
as a potential therapy for disorders in which Dscam expression is increased. Since Appl also 
partially requires Abl to promote presynaptic terminal growth, we hypothesize that tyrosine 
kinase inhibitors may also mitigate the consequences of simultaneous Dscam and Appl 
upregulation. However, future experiments are required to validate this hypothesis. 
4.3 Potential of tyrosine kinase inhibitors as therapeutics for brain disorders  
 One exciting outcome of this work is the potential to use tyrosine kinase inhibitors like 
nilotinib to treat disorders in which Dscam expression is elevated, such as Down syndrome and 
Fragile X syndrome. However, many questions remain before this strategy can be tested in 
human patients. Importantly, we determined the morphological consequences of increased 
Dscam expression in Drosophila neurons. Whether the observed changes in neuronal 
morphology lead to behavioral alterations and deficits in Drosophila is still unknown. However, 
changes in neuronal morphology are observed in both Down syndrome and Fragile X syndrome, 
suggesting that morphological alterations may be causative for intellectual disability in each of 
these disorders (Kaufmann and Moser, 2000). Furthermore, whether treatment with tyrosine 
kinase inhibitors can rescue the behavioral changes seen in Drosophila dFMRP mutants, a fly 
model of Fragile X syndrome, remains to be tested. If treatment with nilotinib can rescue the 
learning and memory and circadian rhythm phenotypes that characterize this model, it would 
suggest that inhibiting tyrosine kinase activity may prove therapeutic for brain disorders with 
increased Dscam expression.  
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 In addition to unknowns in the Drosophila system, the question of whether the Dscam-
Abl pathway is conserved in mammals has yet to be answered. This question can be relatively 
quickly answered by using mammalian cell culture to test whether mammalian Dscam and Abl 
bind to one another and whether mammalian Dscam activates Abl kinase activity in vitro. If 
these properties are conserved, the next step would be to determine whether the Dscam-Abl 
pathway participates in the development of presynaptic arbors in mammals. In this vein, it is 
interesting to note that Abl has been shown to be required for postsynaptic development of the 
NMJ in mice, where it is thought to signal through MuSK to cluster AChRs on the post-synaptic 
myotubule (Finn et al., 2003). Developing a system to assess presynaptic arbor size control in the 
mammalian central nervous system will prove useful for this line of study. 
 In the event that Dscam and Abl are found not to be involved in mammalian presynaptic 
arbor development, it is equally possible that the Dscam-Abl pathway is conserved in mammals 
but mediates different aspects of development. For example, Dscam mutant mice have a variety 
of neurological phenotypes, including severely uncoordinated gait, spontaneous seizures and 
kyphosis. In addition, Dscam mutant mice exhibit retinal abnormalities, including defective 
laminar specificity, neurite arborization, and cell body spacing (Fuerst et al., 2008). Thus, it is 
possible that Abl mediates Dscam’s function in any of these developmental roles. Furthermore, 
several mouse models of Down syndrome, like Ts16, Ts1Cje, and Ts65Dn, have three copies of 
the Dscam gene and have a host of neurological phenotypes that have been well characterized 
(Seregaza et al., 2006). Although it is not yet established which, if any, of these phenotypes are 
the result of increased Dscam expression, this question may be asked by reducing copy number 
of Dscam in these model systems by introducing a single copy of a loss-of-function mutation of 
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Dscam. If any phenotypes caused by increased Dscam expression are discovered, it could then be 
asked whether Abl was required to mediate Dscam’s role in these processes.  
  Finally, it may be possible to test the utility of tyrosine kinase inhibitors as a potential 
therapy for Down syndrome and Fragile X syndrome by directly treating mouse models of these 
disorders with tyrosine kinase inhibitors and evaluate the effects on cognition and behavior. 
Although studies of this kind would not shed light on the mechanism of action, they would 
indicate whether treatment with tyrosine kinase inhibitors might have utility for mitigating the 
cognitive and behavioral consequences of these disorders. The neurological phenotypes of a 
number of mouse models of Down syndrome that include three copies of Dscam have been well 
documented with established behavioral assays, including learning and memory using the Morris 
water maze and fear conditioning tasks, and grip strength (Costa et al., 2010). Furthermore, the 
mouse model of Fragile X syndrome, FMR1 mutant mice, has been shown to have deficits in 
learning and memory using the Morris water maze (Consorthium, 1994) and sensory 
hypersensitivity using the prepulse inhibition paradigm (Chen and Toth, 2001). Thus, it may be 
informative to treat these mouse models with tyrosine kinase inhibitors and assess changes in 
learning and memory, grip strength, and sensory sensitivity using established assays. If tyrosine 
kinase inhibitors positively impact the behavior of these mouse models, it will set the stage for 
clinical trials in humans. 
 One of the unique advantages to using tyrosine kinase inhibitors to treat developmental 
disorders is that a number of tyrosine kinase inhibitors, including imatinib and nilotinib, are 
already approved by the FDA for use in humans, though for treating leukemia. In addition, 
patients with chronic myeloid leukemia may take imatinib or nilotinib continuously for a period 
of years without significant adverse effects(Druker, 2008). However, several unknowns about the 
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feasibility of treating developmental disorders with tyrosine kinase inhibitors remain, including 
whether they are safe for long-term use in pediatric patients. However, several safety studies in 
pediatric patients have already been completed, with promising results. Dasatinib, which is 
known to cross the blood-brain barrier (Porkka et al., 2008), has shown similar efficacy and side 
effects as have been noted in adults in pediatric patients treated for less than 1 month up to 50.6 
months. Like adults, the most common side effects were nausea, headache, diarrhea, and 
vomiting. Importantly, no drug-related deaths were observed (Aplenc et al., 2011; Zwaan et al., 
2013). Nilotinib, which was used in our experiments and is known to cross the blood-brain 
barrier (Hebron et al., 2013), is currently being studied in Phase I and Phase II trials which aim 
to assess the safety and efficacy of treating pediatric chronic myeloid leukemia patients. In the 
meantime, compassionate use studies and case reports suggest that nilotinib has a similar safety 
profile in children as in adults (Wayne, 2008). Thus, existing studies suggest that tyrosine kinase 
inhibitors are likely to be safe for pediatric patients, but further work remains to confirm the 
safety of nilotinib.  
 If tyrosine kinase inhibitors are deemed safe for administration to pediatric patients, 
another challenge for validating these drugs for treating Down syndrome and Fragile X 
syndrome is determining the optimal treatment window.  Though neurological abnormalities in 
Down syndrome and Fragile X syndrome are thought to begin prenatally, treatment in utero is 
unlikely to be an option due to the documented teratogenicity of tyrosine kinase inhibitors in 
mammals. Teratogenicity and fetal loss have been documented in rats and rabbits administered 
imatinib and dasatinib. Although administration of nilotinib did not lead to teratogenicity, studies 
of rats and rabbits indicate a low absorption of nilotinib in the fetus, which could explain the lack 
of teratogenicity (Abruzzese et al., 2014). Low absorption of nilotinib by the fetus may also 
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explain the lack of observed teratogenicity in human patients who continued treatment with 
nilotinib during accidental pregnancies (Conchon et al., 2009; Mseddi, 2012). Though tyrosine 
kinase inhibitors are unlikely to be safe if administered prenatally, postnatal treatment may still 
prove effective. At the time of birth, human cognitive development is still progressing at a rapid 
pace and continues until approximately the onset of puberty (Chugani et al., 1987). Although 
evidence in humans is limited due to the dearth of healthy human tissues for study and of 
patients willing to subject their healthy children to PET imaging, However, limited data suggests 
that synaptogenesis peaks between the ages of 2 and 5 years (Huttenlocher and Dabholkar, 1997; 
Liu et al., 2012). Thus, we believe that treatment with tyrosine kinase inhibitors is likely to 
provide greatest benefit during this critical period of rapid synaptogenesis. Whether treatment 
beyond this 2 to 5 year-of-age period would be likely to prove therapeutic is difficult to speculate 
about. This question might be addressed first in Drosophila or mouse models of Down syndrome 
or Fragile X syndrome, should tyrosine kinase inhibitor treatment show efficacy in treating 
behavioral defects in these models. 
 Despite the many unknowns that remain to be investigated before clinical trials for 
tyrosine kinase inhibitors in Down syndrome and Fragile X syndrome patients commence, we 






Figure 4.1 Summary of Hypotheses. 
My current working hypothesis based on the experiments presented in this dissertation is that 
Dscam and Appl act as coreceptors to activate Abl kinase. In wildtype animals (left), normal 
Dscam and Appl levels mean that some Dscam bind to some Appl, which in turn leads to 
activation of Abl through Abl binding to the Dscam cytoplasmic domain. This, in turn, leads to 
normal presynaptic arbor growth through yet unknown downstream mechanisms. However, in 
conditions like Down syndrome or Fragile X syndrome where Dscam and Appl expression is 
increased, more Dscam and Appl means increased Dscam-Appl binding, which leads to more 
Abl binding to the Dscam cytoplasmic domain and becoming activated. More active Abl then 
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